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Chapter 1: Prelude: A Conceptual Framework for Translational Informatics 
Background 
 Despite medicine’s rigorous pace of advancement, clinical research remains limited 
by scalability and portability issues. All too commonly cancer epidemiology relies on 
manual chart reviews to generate data in a registry-specific or study-specific or manner. 
Further, methodological approaches for integration of data between data sources warrant 
improvement. Recently, the National Cancer Institute (NCI) provided a vision for the 
modernization of cancer epidemiology that highlighted the need for methodological 
developments where biomedical health informatics would be of tremendous value 
(Khoury 2013). Specific aims for methodological improvements included 1) 
incorporation of multilevel analysis into translational research, 2) integration of data 
across the life course, 3) integration of big data science into translational research, and 4) 
reliably capture exposure phenomena on a massive scale (Khoury 2013). Specifically, 
advancement in our understanding and utilization of multilevel modeling is necessary to 
advance our understanding of the complex, multifactorial causes of cancer (Lynch 2013).  
 In the past we have witnessed the field of biomedical informatics grow from its 
infancy in biometry to clinical informatics. However, as we now see the field of 
biomedical informatics approaching data mining and data science we see both a 
tantalizing opportunity for advancement and humbling assessment of the infancy of even 
data standardization and normalization. Further, as we think about the needs of cancer 
epidemiology, we see the need for multilevel modeling powered by scalable and portable 
informatics-driven approaches even more. 
Conceptual Framework 
 For the consideration of the committee I present a conceptual framework that 
guided the integration of biological and population premises across levels of analysis: A 
Multilevel Framework for Translational Informatics (Figure 1.1). Highlighted in this 
framework is the inherent gap between population-level measures and individual-level 
measures, while the center of the research question remains on providing insight into a 
biological phenomenon.   
2 
 Multilevel modeling remains a computationally and logically difficult endeavor to 
pursue.  Each level in a multilevel model requires precise and specific measures to 
appropriately attribute the construct of relevance (i.e. systematic phenotyping). However, 
within each level of the model, constructs will be logically confounded with one another. 
For example, you do not want to attribute distal effects of social environment to clinical 
biomarkers of breast cancer. Or conversely, you do not want to attribute the beneficial 
effect of a drug on all-cause mortality to cancer-specific mortality. While often the 
confounding cannot be removed, approaches aimed at understanding the latent 
characteristics around these constructs can provide some level of clarity for the purpose 
of modeling phenomena across multiple levels, an approach that is utilized directly in the 
second part and indirectly in the third part.  
Figure 1.1: A Multilevel Framework for Translational Informatics 
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metformin in breast cancer and type 2 diabetes mellitus that is centered around this 
framework. Of particular novelty is a multilevel approach that addresses the NCI’s above 
four specific aims and is powered by testable molecular and population-level premises to 
elucidate clinical-level questions regarding the potential repurposing of metformin for 
breast cancer treatment. In what follows I present three topics, consisting of the 
reproductions of four scientific papers, that as of the time of the writing are currently 
under review: 1) metformin and insulin pharmacoepidemiology, 2) the modifying impact 
of socioecological context on breast cancer prevalence, and 3) translational biomedical 
informatics of metformin pharmacogenomics. While this work elucidates aspects of 
metformin pharmacogenomics, it primarily aims to demonstrate this framework for 
utilizing informatics approaches to drive metformin pharmacoepidemiology and 
translational pharmacogenomics for potential metformin repurposing in breast cancer 
treatment and similar research in the future. 
Overview 
 Metformin is an oral biguanide and is a widely prescribed anti-diabetic medication 
(Thompson 2014) that is considered to be a first-line treatment for T2DM (Inzucchi 
2012). While metformin if generally well tolerated (Gong 2012) its pharmacogenomics 
are not clearly understood and approximately 30% of patients do not respond to it. Due to 
the epidemic growth of T2DM in the US and the accumulating evidence highlighting 
potential repurposing of metformin for cancer prevention and treatment it is imperative to 
understand molecular mechanisms and clinical impacts of metformin. Further, in order to 
appropriately separate effects due to metformin and breast cancer from social stress, a 
known modifier of breast cancer biology, it is necessary to incorporate this characteristic 
into the model in a way that does not lead to over fitting. Below I provide a brief abstract 
of the corresponding part and chapter components. 
Part #1: Pharmacoepidemiology of Metformin in Breast Cancer 
 Metformin use in type 2 diabetes mellitus (T2DM) patients has been shown to 
reduce the incidence of breast cancer. However, the impact of metformin and insulin on 
breast cancer specific survival outcomes remains controversial. Further, the impact of 
4 
metformin and insulin on breast cancer-specific mortality outcomes beyond those 
attributable to mortality outcomes due to T2DM severity remains unclear. In this part, I 
evaluated the effect for metformin and insulin on mortality outcomes using a traditional 
and alternate analysis approach, which I am going describe in the following two chapters, 
respectively.  
Chapter 2: Association of Metformin Exposure with Breast Cancer Survival 
 In this chapter I utilized electronic health record (EHR) augmented cancer registry 
data and standard survival analysis approaches to model the effect of metformin and 
insulin on all cause and breast cancer-specific mortality outcomes in patients with breast 
cancer and T2DM. This standard approach left confounded the implications for 
metformin and insulin that was due to T2DM severity and for breast cancer-specific 
mortality outcomes. 
Chapter 3: Disease-Specific Effects of Metformin in Breast Cancer Patients with 
Type II Diabetes Mellitus 
 In this chapter I utilized an alternative analysis approach that aimed to separate the 
effects of metformin and insulin due to T2DM severity and for breast cancer treatment 
outcomes using a trained linear offsets for T2DM severity. 
Part #2: Accounting for Socioecological Context in Clinical Research 
Neighborhoods and social structure are known to impact health. However, 
population attributes are commonly confounded with each other and latent measures are 
commonly skewed by limited inter-neighborhood comparison, limiting our ability to 
quantify causality. While causal estimations of neighborhood effects cannot be reliably 
attained, translational research endeavors benefit from utilizing robust phenotypes that 
incorporate socio-ecological context. Further, translational research also stands to benefit 
from novel approaches that allow for more nuanced stratification between phenotypes 
and facilities that go beyond the potentially problematic standard practice of simply 
placing the facility as a random effect or socioeconomic status as an additive effect in 
clinical research models. The aim of this work was to develop a population-based risk 
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adjustment index that accounted for socio-ecological context using a generalizable 
approach that enables future translational research. 
Chapter 4: Community-Based Measures of Social Stress on Breast Cancer 
Prevalence 
 Due to the confounding relationship between clinical and social factors it is likely 
that the effect of socio-ecological conditions (SECs) is being inappropriately attributed to 
clinical variables in retrospective clinical research. Utilizing validated measures of social 
stress as the SEC of interest, obesity as the clinical indicator of interest, and breast cancer 
prevalence as the clinical outcome of interest, we demonstrated the impact of isolating 
SECs from the effect of clinical indicators in clinical research models. I demonstrated the 
need to account for SECs to more appropriately model clinical indicators that impact 
clinical outcomes. 
Part #3: Leveraging the Electronic Health Record-Linked Biorepository in 
Translational Biomedical Informatics 
 Metformin is a first-line antihyperglycemic agent commonly prescribed in type 2 
diabetes mellitus (T2DM), but whose pharmacogenomics are not clearly understood. 
Approximately 30% of patients do not respond to metformin with outcomes ranging from 
no impact on glycemic control to adverse reactions; it is imperative to understand 
molecular mechanisms of metformin further. In this part I sought to understand the 
impact of variants in candidate genes thought to modify glycemic response to metformin 
treatment using EHR-linked genetic data. 
Chapter 5: The Impact of Genomic Variation in Metformin Pharmacogenomic 
Determinants on Glycemic Response  
 Seventeen genes with suspected pharmacokinetic or pharmacodynamic implications 
were selected based on systematic review for study. Our analysis cohort consisted of 258 
T2DM patients who had new metformin exposure, existing genomic data, and 
longitudinal electronic health records. Change in glycemic response to metformin 
exposure via A1c measures pre and post metformin exposure serve as the outcome of 
interest. After quality control, gene-level and SNP-level analysis were conducted on 17 
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candidate genes and 463 SNPs within those genes, controlling for key covariates of sex, 
age, and body mass index (BMI) at index metformin exposure.  
Chapter 6: Leveraging the Electronic Health Record(EHR)-Linked Biorepository: 
An EHR-Driven Hypothesis for Glycemic Response to Metformin 
 In this part I explored the potential association of the flavin-containing 
monooxygenase(FMO)-5 gene, a biologically plausible biotransformer of metformin, and 
modifying glycemic response to metformin treatment. Using a cohort of 258 T2DM 
patients who had new metformin exposure, existing genetic data, and longitudinal 
electronic health records, I compared genetic variation within FMO5 to change in 
glycemic response. Gene-level and SNP-level analysis identified marginally significant 
associations for FMO5 variation, representing an EHR-driven pharmacogenetics 
hypothesis for a potential novel mechanism for metformin biotransformation. However, 
functional validation of this EHR-based hypothesis is necessary to ascertain its clinical 
and biological significance.  
Part #5: Conclusion 
Chapter 7: Conclusion for the Framework on Translational Informatics 
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Part #1: Pharmacoepidemiology of Metformin in Breast Cancer 
 Metformin use in type 2 diabetes mellitus (T2DM) patients has been shown to 
reduce the incidence of breast cancer. However, the impact of metformin and insulin on 
breast cancer specific survival outcomes remains controversial. Further, the impact of 
metformin and insulin on breast cancer-specific mortality outcomes beyond those 
attributable to mortality outcomes due to T2DM severity remains unclear. In this part, I 
first demonstrate associations for metformin and insulin on breast cancer specific 
mortality outcomes using survival analysis using EHR data. Finally, I demonstrated a 
significant protective effect for metformin and a significant detrimental effect for insulin 
on breast cancer survival outcomes that is beyond their implication T2DM severity using 
linear offsets to separate effects. 
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Chapter 2: Association of Metformin and Insulin Exposure with Breast Cancer 
Survival Outcomes 
Abstract 
Purpose 
While metformin use in diabetic patients has been shown to reduce the incidence 
of breast cancer, the impact of metformin on survival after breast cancer incidence still 
remains unclear. Previous studies have been limited by small cohort size and missing key 
clinical attributes. Using electronic health record (EHR) data we examined metformin 
exposure after breast cancer diagnosis on mortality outcomes by breast cancer subtype. 
Patients and Methods 
1,180 patients with unilateral, non-recurrent breast cancer diagnosis between 1998 
and 2011 and type II diabetes mellitus were identified using a combination of manual 
chart review and phenotyping of electronic health records. Median age at breast cancer 
diagnosis was 67(34-95) and median follow-up time was 83 (6-191) months. Exposure to 
metformin was defined as ≥6 months of known exposure after breast cancer diagnosis. 
Univariate, multivariate, and stratified Cox Proportional Hazard Regression was utilized 
to model metformin exposure and survival outcomes.  
Results 
Univariate survival analysis identified significant associations for metformin 
exposure (n=330) after breast cancer diagnosis on decreased all cause mortality 
(HR=0.680,p=0.0131) and decreased breast cancer-specific mortality 
(HR=0.433,p=0.0195) outcomes. Multivariate analyses identified a consistent significant 
protective association between metformin exposure and breast cancer-specific mortality 
and a consistent detrimental association between insulin exposure and breast cancer-
specific mortality during the same period. Potential treatment and severity interaction 
were identified during iterative model development. After developing an overall drug 
exposure model controlling for key covariates of patient demographics, severity, and 
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treatment metformin demonstrated a significant protective association (HR=0.269,p-
val=0.0378) with breast cancer specific mortality. 
Conclusion 
This study demonstrates a consistent overall protective association for metformin 
exposure after breast cancer diagnosis with decreases in all cause and breast cancer-
specific mortality. While potentially valuable treatment and severity interaction were 
uncovered, increased power is needed to effectively evaluate these interactions. 
Background and Introduction 
 Women with type II diabetes mellitus (T2DM) are at an increased risk of breast 
cancer incidence1. Further, the risk of cancer-related mortality is also increased in cancer 
patients with T2DM, including breast cancer2. While metformin use in diabetic patients 
appears to decrease the risk of breast cancer incidence3, studies aimed at understanding 
the impact of metformin on survival for breast cancer patients have only identified 
significant positive associations for all cancer metformin exposure and all cause 
survival2. Specifically, metformin exposure before and after breast cancer incidence 
among patients with T2DM did not exhibit a statistically significant association with all 
cause survival outcomes2 and cumulative duration of metformin exposure after T2DM 
diagnosis did not exhibit an association with all cause and breast cancer-specific survival 
in an aged cohort4. Among studies evaluating specific types of breast cancer, metformin 
exposure was associated with improved overall survival outcomes for stage ≥2 HER2+5 
but not for triple receptor-negative receptor breast cancer treated with chemotherapy6.  
 Consequently, the association of metformin exposure with all cause and breast 
cancer-specific mortality remains unclear. Previous studies aimed at understanding this 
relationship have been limited by lacking disease-specific mortality information or by 
lacking access to data available in an electronic health record (EHR). Our current study 
aims to use an age representative and typologically diverse cohort of women with breast 
cancer and T2DM, augmented with EHR data, to understand this association. 
Specifically, we aim to study if a protective association exists between metformin 
exposure after diagnosis of breast cancer and all cause and breast cancer-specific 
10 
mortality. Our preliminary finding of a potential association between metformin exposure 
and survival has potentially profound implications for breast cancer therapy. Specifically, 
this potential association has direct pharmacogenetic implications for inhibiting breast 
cancer cell growth by targeting components of the adenosine monophosphate-activated 
protein kinase (AMPK)7 pathway, the insulin/insulin-like growth factor-1 (IGF1)8 
signaling pathway, and directly and indirectly via additional pathways9 with specific drug 
therapy combinations.  
Materials and Methods 
 Cohort inclusion was limited to female patients with a non-recurrent confirmed 
diagnosis of unilateral breast cancer and T2DM. Inclusion was also limited to eligible 
new breast cancer cases between the years 1998 and 2011 to allow for a minimum two 
year follow-up period. Male patients and those with type I diabetes mellitus or ambiguous 
diabetes type were excluded from this study. Patients with survival or follow-up < 6 
months were silenced from the cohort to control for immortal time bias. Metformin and 
insulin exposure were parameterized to represent >=6 months of drug exposure within 
the treatment period post breast cancer diagnosis. Patients needed to have multiple 
recorded mentions of an individual class of antidiabetic medications spanning a period of 
greater than 30 days to be considered as having exposure to an individual class of 
antidiabetic medications. Patients without multiple recorded mentions of an individual 
class of antidiabetic medications spanning more than 30 days post breast cancer diagnosis 
were parameterized as not having exposure to individual class of antidiabetic medications 
(n=25 for metformin). The resulting cohort contained female patients (n=1,180) with 
unilateral, non-recurrent breast cancer diagnosis who had a median age of breast cancer 
diagnosis of 67 (34-95) years and median follow-up period of 83 (6-191) months. A 
description of the cohort can be found in Table 2.1. 
Table 2.1.  Descriptive statistics of cohort. 
  event all 
Demographics 
  
all cause mortality 306 1188 
breast cancer-specific mortality 71 1053 
follow up period 83 (6 , 191) 1188 
11 
age at diagnosis of breast cancer 67 (34 , 95) 1188 
resident of rural zip code 277 1162 
Primary care patient     
white 1072 1188 
Antidiabetic Therapies 
  
metformin 355 
1188 
insulin 245 
tzd 73 
sulfonylurea 182 
Diabetic Severity 
  
A1c   6.5 (4.5 , 15.1) 
687 uncontrolled diabetes 205 
BMI   31.8 (14.5 , 61.7) 1135 
  
  
  
  
  
underweight 5 
normal 149 
overweight 281 
moderately obese 324 
severely obese 376 
Breast Cancer Severity 
  
Stage In Situ 185 1152 
  
  
  
  
1 596 
2 14 
3 240 
4 25 
Grade 1 197 1188 
  
  
  
2 424 
3 273 
4 294 
Breast Cancer Receptor Status 
  
Estrogen Receptor Positive 772 886 
Progesterone Receptor Positive 695 864 
HER2/neu status actionable  527 906 
  HER2/neu positive 98 906 
Triple Negative 31 864 
Breast Cancer Treatment 
  
Surgery 444 979 
Chemotherapy 242 1174 
Radiation Therapy 227 890 
Hormone therapy 503 1168 
Immuno therapy 12 1187 
Fulvestrant 43 1188 
Aromatase Inhibitors 567 1188 
Herceptin 96 1188 
Methotrexate 72 1188 
Ovarian ablation 23 1188 
Selective estrogen response modulators 918 1188 
Charlson Comorbidity Index 
  Myocardial Infarction 73 1188 
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 Diagnosis, medication, patient attributes, and last follow-up data points were 
extracted from Mayo Clinic’s Enterprise Data Trust10 and electronic death certificate data 
containing ICD-10-CM codes between the years 2000 and 2013 for underlying and direct 
cause of death were extracted from Minnesota Electronic Death Certificates. Survival 
time was defined as the duration in months between first identified diagnosis of breast 
cancer and censor or death date. If a patient was not identified as deceased from either the 
Minnesota Death Registry or Mayo Clinic’s EHR, patient survival time was censored at 
the last known follow-up date. Kaplan-Meier analysis was used to calculate unadjusted 
survival models and Cox Proportional Hazard Regression was utilized to calculate 
adjusted survival models. All statistical analysis was performed using Linux SAS v9.3 
and data visualization was assisted by a SAS macro for Cox Proportional Hazard 
Regression11. 
Results 
Univariate survival analysis demonstrated a protective association of metformin 
exposure after breast cancer diagnosis with decreases in all cause mortality (HR=0.680,p-
val=0.0131) and breast cancer-specific mortality (HR=0.433,p-val=0.0195). Since 
elucidating the impact of metformin in this cohort of patients requires considerations for 
Congestive heart failure 159   
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
peripheral vascular disease 132 
cerebrovascular disease 166 
Dementia 62 
chronic pulmonary disease 263 
ulcer 88 
mild liver disease 119 
Diabetes 1188 
Diabetes with organ damage 206 
hemiplegia 20 
moderate/severe renal disease 135 
moderate/severe liver disease 24 
metastatic solid tumor 394 
Aids 0 
Rheumatologic disease 66 
Cancer 1188 
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both T2DM (Table 2.2) and breast cancer (Table 2.3), a series of sensitivity analyses 
were utilized to identify parameters appropriate for stratification in the final drug 
exposure model. 
T2M considerations 
  Multivariate analysis of common classes of antidiabetic therapies (Table 2.2) 
(metformin, insulin, thiazolidinedione, sulfonylurea) identified metformin as having a 
strongly significant protective association on all cause mortality (HR=0.500,p-
val<0.0001) and breast cancer-specific mortality (HR=0.248,p-val=0.0003) and insulin as 
having a strongly significant detrimental association on all cause mortality (HR=2.361,p-
val<0.0001) and breast cancer-specific mortality (HR=3.190,p-val<0.0001) (Table 2.2a). 
In order to identify potential bias amongst classes of antidiabetic medication exposure by 
glycemic control of diabetes (A1c < 7), a potentially confounding factor and proxy for 
diabetes severity, we evaluated these medications in a subgroup of patients with A1c 
measurements in the EHR (n=687). Glycemic control of diabetes was found not to be 
associated with significant detrimental associations on breast cancer specific mortality 
Table 2.2: Classes of Antidiabetic Medications 
Table 2.2a:  
Antidiabetic 
Therapies 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI -
low 
CI - 
high HR p-val 
CI -
low 
CI - 
high 
  
Metformin 0.500 <0.0001 0.357 0.702 0.248 0.0003 0.117 0.527 
Insulin 2.361 <0.0001 1.765 3.159 3.190 <0.0001 1.848 5.506 
Thiazolid-
inedione 1.258 0.3594 0.770 2.056 2.163 0.0700 0.939 4.981 
Sulfonylurea 1.264 0.2194 0.870 1.835 1.458 0.2987 0.716 2.971 
  
Table 2.2b:  
Glycemic 
Control 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI -
low 
CI - 
high HR p-val 
CI -
low 
CI - 
high 
  
Metformin 0.458 <0.0001 0.317 0.662 0.275 0.0016 0.123 0.612 
Insulin 1.513 0.0156 1.082 2.117 2.042 0.0302 1.071 3.893 
Thiazolid-
inedione 0.949 0.8564 0.536 1.678 1.015 0.9780 0.342 3.014 
Sulfonylurea 1.010 0.9641 0.667 1.529 1.444 0.3425 0.676 3.085 
Uncontrolled 
diabetes 1.478 0.0117 1.091 2.003 1.285 0.4475 0.673 2.455 
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(HR=1.285,p-val=0.4475), and had only a minimal impact on the calculated risk of breast 
cancer specific mortality for metformin (HR=0.275,p-val=0.0016) and insulin 
(HR=2.042,p-val=0.0302) (Table 2.2b). Since glycemic control of diabetes was 
demonstrated as having no significant impact on breast cancer specific survival outcomes 
it was dropped from future multivariate models. 
Breast cancer staging and severity considerations 
After controlling for specific elements breast cancer staging and severity (Table 
2.3a), adjusted survival analysis demonstrated a protective association of metformin 
exposure after breast cancer diagnosis with decreases in all cause mortality (HR=0.544,p-
val=0.0005) and breast cancer-specific mortality (HR=0.3000,p-val=0.0020). Parameters 
for chemotherapy and surgery status appeared to capture breast cancer severity and were 
included in the final model. Considerations for breast cancer biology (Table 2.3b) 
demonstrated detrimental associations for HER2 negative patients, while still 
demonstrating similar protective association of metformin exposure after breast cancer 
diagnosis with decreases in all cause mortality (HR=0.542,p-val=0.0010) and breast 
cancer-specific mortality (HR=0.343,p-val=0.0078). Since the majority of patients were 
estrogen (87.1%) or progesterone (80.4%) positive (90.0%) it was expected ER/PR status 
would not deviate the median fit of the model. HER2 negative status was marked for 
inclusion in the final model. 
Breast cancer treatment considerations  
A combined model of breast cancer drug therapy and select diabetes medications 
to identify potential drug interaction effects and elucidate the potential effect of 
metformin (Table 2.3c). Fulvestrant (HR=7.045,p-val<0.0001) and methotrexate 
(HR=2.450,p-val=0.0060) had significant detrimental associations with breast cancer 
specific mortality (Table 2.3d). SERMS having marginally significant (HR=0.616,p-
val=0.0904) protective associations on breast cancer specific mortality (Table 2.3d). 
Interactions were detected between metformin and fulvestrant (HR=10.025,p-
val=0.0002) and insulin and trastuzumab (HR=25.743,p-val<0.0001) using backwards 
elimination on breast cancer and select diabetes drug therapy interactions (Table 2.3e). 
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Patients exposed to both metformin and fulvestrant therapy (n=8) suffered a mortality 
event within 7 years (n=4), 3 of which were known to be breast cancer-specific mortality 
events. It is important to note that these associations cannot be interpreted as having 
actual or clinical significance due to potential model over fitting and instability due to a 
small (n=7) number of interaction events.  
Table 2.3: Breast Cancer Staging and Severity 
 
Table 2.3a: Breast 
Cancer severity 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI-
low 
CI-
high HR p-val 
CI-
low 
CI-
high 
  
Metformin 0.544 0.0005 0.386 0.768 0.300 0.0020 0.139 0.644 
Insulin 2.240 <0.0001 1.642 3.055 3.254 <0.0001 1.837 5.766 
In situ 0.431 0.0004 0.271 0.685 0.356 0.0547 0.124 1.021 
High grade 1.292 0.0658 0.983 1.698 1.613 0.0851 0.936 2.779 
Chemotherapy 0.811 0.2277 0.577 1.140 2.008 0.0134 1.155 3.488 
Surgery 0.478 <0.0001 0.364 0.628 0.544 0.0265 0.317 0.931 
Table 2.3b: Breast 
Cancer biology 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI-
low 
CI-
high HR p-val 
CI-
low 
CI-
high 
  
Metformin 0.542 0.0010 0.038 0.780 0.343 0.0078 0.156 0.754 
Insulin 2.758 <0.0001 1.974 3.853 3.907 <0.0001 2.065 7.393 
ER positive 1.038 0.8922 0.607 1.774 0.853 0.7535 0.315 2.308 
PR positive 0.656 0.0691 0.416 1.034 0.540 0.1527 0.232 1.256 
her2 actionable, 
positive 1.227 0.3971 0.765 1.968 1.941 0.1805 0.735 5.121 
her2 actionable, 
negative 1.406 0.0399 1.016 1.945 2.396 0.0175 1.166 4.925 
Table 2.3c: Breast 
Cancer biology 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI-
low 
CI-
high HR p-val 
CI-
low 
CI-
high 
  
Metformin 0.658 0.0110 0.477 0.909 0.389 0.0114 0.188 0.808 
Insulin 2.620 <0.0001 1.955 3.511 3.281 <0.0001 1.916 5.619 
Anti-estrogens 2.898 <0.0001 1.846 4.548 7.045 <0.0001 3.508 
14.15
1 
Aromatase 
inhibitors 0.681 0.0045 0.523 0.888 0.902 0.7173 0.518 1.573 
Herceptin 1.252 0.2940 0.823 1.906 1.568 0.1948 0.794 3.094 
Methotrexate 1.495 0.0511 0.998 2.238 2.450 0.0060 1.293 4.644 
Ovarian oblation 0.179 0.3257 0.179 1.771 1.108 0.8682 0.330 3.720 
SERM 0.453 <0.0001 0.353 0.581 0.616 0.0904 0.351 1.079 
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Table 2.3d: Backwards elimination  Breast Cancer-Specific Mortality 
Association 
Chi-
Square p-val S.E. 
  
Metformin Protective 7.377 0.0066 0.445 
Insulin Detrimental 7.625 0.0058 0.344 
Anti-estrogens Detrimental 26.348 <0.0001 0.383 
Metformin*Anti-Estrogens Detrimental 4.748 0.0293 0.794 
Aromatase inhibitors Detrimental 0.508 0.4760 0.306 
Herceptin Detrimental 4.070 0.0437 0.645 
Insulin*Herceptin  Detrimental 3.478 0.0622 0.811 
Aromatase inhibitors*Herceptin  Protective 12.632 0.0004 0.768 
Methotrexate Detrimental 2.282 0.1309 0.464 
 
Table 2.3e: Medication 
Interaction Model 
Breast Cancer-Specific Mortality 
Association HR p-val L-CI H-CI 
  
Metformin Protective 0.261 0.0024 0.110 0.622 
Insulin Detrimental 3.180 <0.0001 1.778 5.686 
Anti-estrogens Detrimental 7.614 <0.0001 3.643 15.914 
Metformin*Anti-Estrogens Detrimental 10.025 0.0002 2.967 33.878 
Aromatase inhibitors Detrimental 1.063 0.8331 0.601 1.880 
Herceptin Detrimental 4.346 0.0077 1.476 12.795 
Insulin*Herceptin  Detrimental 25.743 <0.0001 8.259 80.239 
Aromatase 
inhibitors*Herceptin  Protective 0.525 0.3295 0.144 1.918 
Methotrexate Detrimental 1.983 0.0456 1.013 3.879 
Stratified drug exposure model 
 Using a machine learning approach to identify key covariates from the above 
components a final model of drug exposure was developed (Table 2.4). Age at diagnosis 
of breast cancer, obesity status, rural resident, high-grade breast cancer, in situ breast 
cancer, chemotherapy, surgical intervention, and Charlson Comorbidity Index >8 were 
stratified in the final drug exposure model. Metformin was identified to have a protective 
association with overall (HR=0.545,p-val=0.0059) and disease specific mortality 
(HR=0.269,p-val=0.0378). 
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Table 2.4: Overall Model Stratified by Key Covariates 
Stratified* 
Model 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val CI-low CI-high HR p-val CI-low CI-high 
  
Metformin 0.545 0.0059 0.354 0.840 0.269 0.0378 0.078 0.929 
Insulin 1.438 0.0695 0.971 2.129 2.147 0.1321 0.794 5.802 
Anti-
estrogens 2.013 0.0316 1.064 3.809 2.806 0.1189 0.767 10.266 
Herceptin 1.117 0.8641 0.314 3.973 2.253 0.5067 0.205 24.771 
Methotrexate 1.073 0.8190 0.601 1.919 2.135 0.2157 0.643 7.096 
Metformin*a
nti estrogen 4.757 0.0506 0.996 22.714 9.750 0.1067 0.613 155.116 
* stratified by: Age at diagnosis of breast cancer, BMI >=35, rural residence, high grade cancer, 
in situ cancer, chemotherapy, surgical intervention 
 In summary, metformin exposure after breast cancer diagnosis appeared to have a 
significant protective association with all cause survival in both the unadjusted and 
adjusted models, whereas insulin appeared to have a significant detrimental association 
with breast cancer-specific survival. However, it is still not clear if the protective and 
detrimental associations for metformin and insulin, correspondingly, are due truly to a 
treatment effect during the course of breast cancer treatment or due to their implications 
for T2DM severity. 
Discussion 
 While existing literature points to a decreased incidence of breast cancer in diabetic 
patients exposed to metformin3, existing studies2,4 have measured metformin exposure 
occurring after T2DM incidence and have not clearly addressed metformin exposure 
occurring after breast cancer incidence. Further these studies were limited by lacking 
either clinical EHR data or cause of death data and may have confounded measures of 
incidence and survival when studying the impact of metformin. Our study limited 
potential confounding of incidence with survival by focusing on metformin exposure 
occurring only after breast cancer diagnosis.  
 While this analysis remains preliminary, the findings hint that a protective 
association between long-term metformin exposure after breast cancer diagnosis and all 
cause and breast cancer-specific survival in a cohort of breast cancer and T2DM patients 
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may exist. The unadjusted models demonstrated a significant positive association with 
overall survival, while the adjusted models display a significant protective association 
between long-term metformin exposure after diagnosis of breast cancer as well as all 
cause and breast cancer-specific survival. Some confounding relationships were 
accounted for in the adjusted models, while others remain to be addressed in future work: 
Drug relationships including metformin exposure prior to breast cancer diagnosis and 
exposure to other antidiabetic therapies, including insulin, thiazolidinedione, and 
sulfonylurea concurrent and non-concurrent with metformin exposure. Breast cancer 
severity, receptor status, grade, stage, surgery status, and treatment regiment need to be 
utilized. Finally, the most important confounding that remains to be addressed in future 
work is disambiguating between changes in breast cancer survival outcomes due to 
metformin and insulin implications for T2DM severity and their implication as a potential 
treatment effect in breast cancer. 
 Future research will broaden focus with a larger cohort to understand if metformin 
exposure both lowers incidence of breast cancer and increases survival outcomes and to 
what extent. Specifically, metformin exposure in certain individuals may have already 
lowered the risk of developing breast cancer to a threshold where metformin exposure 
after breast cancer diagnosis becomes ineffective. Additional analysis will aim to ensure 
cohort homogeneity between exposure groups and appropriate model weighting. Some 
specific analytic approaches will include marginal structural modeling and penalized Cox 
regression. 
 In conclusion, these findings hint at a potential protective relationship between 
length of metformin exposure occurring after breast cancer diagnosis and increased 
survival outcomes. While compelling, adjusted estimates of survival remain preliminary 
and should be interpreted with caution until fully vetted in future survival research, but 
provide a foundation to proceed forward with future pharmacogenetic and translational 
genetic pathway research. 
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Chapter 3: Disease-Specific Effects of Metformin in Breast Cancer Patients with 
Type II Diabetes Mellitus 
Abstract 
Purpose 
 While metformin use in type 2 diabetes mellitus (T2DM) patients has been shown 
to reduce the incidence of breast cancer, the impact of metformin and insulin on breast 
cancer specific survival outcomes remains unclear. Further, due to the implications of 
metformin and insulin for T2DM severity, the impact of metformin and insulin on 
mortality outcomes beyond those attributable to T2DM severity remains unclear.  
Patients and Methods 
 1,180 female patients with unilateral, non-recurrent breast cancer diagnosis 
between 1998 and 2011 and T2DM at breast cancer diagnosis were identified using Mayo 
Clinic electronic health record (EHR) data. Median age at breast cancer diagnosis was 67 
(34-95) and median follow-up time was 83 (6-191) months. Stratified Cox proportional 
hazard regression was utilized to separate the effects of metformin (n=299) and insulin 
(n=197) ≥6 months on T2DM severity (breast cancer-specific mortality events removed) 
and breast cancer treatment outcomes. A linear offset of T2DM severity was utilized to 
separately study the effect of metformin and insulin in multivariate Cox models of breast 
cancer treatment and biology. 
Results 
 Significant univariate associations on breast cancer specific mortality were 
observed for metformin exposure (n=322, HR=0.293 ,p=0.0042) and insulin exposure 
(n=218, HR=0.2.889, p<0.0001). Significant protective effects for metformin (HR=0.544,  
p=0.0017) and detrimental effects for insulin (HR=2.144, p<0.0001) were observed due 
to their implication for T2DM severity. For breast cancer-specific disease impact, 
significant (p<0.0500) effects in models of breast cancer treatment and biology adjusted 
for T2DM severity were observed for metformin (HRs=0.388, 0.339) and insulin 
(HRs=1.956, 2.201). 
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Conclusion 
 In this EHR-driven study, we have demonstrated a significant protective effect for 
metformin and a significant detrimental effect for insulin on breast cancer survival 
outcomes that is beyond their implication T2DM severity. 
Background and Introduction 
 Metformin is an oral biguanide and is a widely prescribed anti-diabetic medication 
(Thompson 2014) that is considered to be a first-line treatment for T2DM (Inzucchi 
2012) and is well tolerated (Gong 2012). The pharmacological effect of Metformin is 
marked by inhibition of hepatic glucose production, reduced intestinal glucose 
absorption, and improved glucose uptake and utilization throughout the body (Gong 
2012). Women with type II diabetes mellitus (T2DM) are at an increased risk of 
developing breast cancer (Boyle 2012). However, a prospective study of metformin for 
diabetes therapy has showed a decrease in breast cancer incidence below rates for 
patients without T2DM, with fewer ER and PR positive cases and fewer HER2 negative 
cases observed (Chlebowski 2012). Further, evidence suggests that insulin may influence 
cancer prognosis (Pollak 2008). 
 While preclinical evidence exists to suggest potential repurposing of metformin for 
breast cancer treatment (Thompson 2014), retrospective and clinical evidence for 
metformin treatment in breast cancer is insufficient. Specifically, inconclusive evidence 
exists of the associations between metformin exposure after breast cancer diagnosis and 
breast cancer specific mortality (Zhang 2014). Eight studies have addressed the impact of 
metformin on all cause mortality outcomes (He 2012, Hou 2013, Peeters 2013, Xiao 
2014, Lega 2013, Bayraktar 2012, Currie 2012), with four of these studies (He 2012, Hou 
2013, Peeters 2013, Xiao 2014, Xu 2014) identifying a significant protective association 
between metformin therapy and all-cause mortality. However, substantial heterogeneity 
between cohorts and substantially different approaches to control for residual 
confounding in analysis was observed among these studies (Zhang 2014). Further, only 
three studies have addressed the impact of metformin on breast-cancer specific mortality 
(He 2012, Lega 2013, Peeters 2013), with one study reporting a significant protective 
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association (HR = 0.47,p=0.023) between metformin exposure and risk of breast cancer-
specific mortality (He 2012). However, that study was limited to a small number of 
patients (n=154) with stage >=2 HER2+ breast cancer and T2DM. Heterogeneity among 
studies may be due to methodological limitations of variable adjustment for differing 
confounding factors (Lega 2014). A protective association for HER2 positive cases was 
demonstrated for metformin exposure after breast cancer incidence on breast-cancer 
specific survival (He 2012). However, associations between metformin exposure and 
survival were not demonstrated for patients with triple negative breast cancer (Bayraktar 
2012). 
 Metformin use in nondiabetic, newly diagnosed breast cancer patients is subject to 
active clinical trials. Prospective window of opportunity clinical trials in non-diabetic 
breast cancer patients have identified associations between metformin exposure prior to 
surgery and anti-cancer effects (Hadad 2011, Niraula 2012). A phase III clinical trial 
(NCIC CTG MA.32) evaluating the effect of adjuvant metformin exposure on recurrence 
and mortality outcomes in non-diabetic, early-stage breast cancer patients is ongoing 
(Goodwin 2011). A Phase II clinical trial (NCT00909506) testing adjuvant metformin 
therapy in overweight or pre-diabetic patients is currently underway. 
 Sufficient evidence does not exist to make inferences regarding the potential impact 
of metformin exposure after breast cancer diagnosis on breast cancer-specific mortality 
outcomes. While the ongoing trial has the potential to clarify this issue in early stage 
patients, further population analysis is needed to elucidate associations by biological 
subgroups. Specifically, plausible additive or interaction effects of metformin and breast 
cancer therapies need to be evaluated. More broadly, we need to understand the overall 
association of metformin exposure with breast cancer-specific mortality outcomes in an 
age-representative cohort with robust clinical indicators. Using robust clinical indicators 
contained within the electronic health record (EHR), our study aims to add clarity to this 
ongoing dialogue by evaluating the impact of metformin use after breast cancer diagnosis 
and potential drug interactions with survival outcomes in an age-representative and 
typologically diverse cohort of women with breast cancer and T2DM. This study isolates 
the effect of metformin exposure (>= 6 months) during the treatment period following 
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breast cancer diagnosis for breast cancer treatment outcomes beyond its implications for 
T2DM severity. Additionally, this study follows a similar progression evaluating the 
effect of insulin due to its potential modifying effect on breast cancer treatment 
outcomes. 
Materials and Methods 
 Using a combination of manually attributed cancer registry for breast cancer 
patients, structured queries, and natural language processing (NLP) a cohort of 13,163 
eligible women with unilateral, non-recurrent breast cancer was identified. Diagnosis of 
breast cancer was confirmed by inclusion in the Mayo Clinic Cancer Registry for breast 
cancer, non-recurrent cancer status was confirmed by using a combination of structured 
EHR and cancer registry data. Breast cancer receptor status was attributed via an NLP 
algorithm of clinical notes (under review). 72.2% of patients had complete breast cancer 
receptor status information available. Manual chart review was performed on 96.4% of 
patients to confirm breast cancer receptor status. Attribution of a T2DM phenotype was 
performed using modified methodology developed by eMERGE (Kho 2012), where 
1,188 patients were identified as having T2DM and breast cancer. Diagnosis, patient 
attributes, and last follow-up data points were extracted from the EHR. Medication 
exposure was extracted from a combination of structured EHR data and NLP of 
medication reconciliation forms (Pathak 2011). Disease specific mortality was identified 
from electronic death certificate data from Minnesota Electronic Death Certificates. If a 
patient was not identified as deceased from either the Minnesota Death Registry or Mayo 
Clinic’s EHR, patient survival time was censored at the last known follow-up date.  
 Cohort inclusion was limited to female patients with a non-recurrent confirmed 
diagnosis of unilateral breast cancer and T2DM. Inclusion was also limited to eligible 
new breast cancer cases between the years 1998 and 2011 to allow for a minimum two 
year follow-up period. Male patients and those with type I diabetes mellitus or ambiguous 
diabetes type were excluded from this study. Patients with survival or follow-up < 6 
months were silenced from the cohort to control for immortal time bias. Metformin and 
insulin exposure were parameterized to represent >=6 months of drug exposure within 
the treatment period post breast cancer diagnosis. Patients needed to have multiple 
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recorded mentions of an individual class of antidiabetic medications spanning a period of 
greater than 30 days to be considered as having exposure to an individual class of 
antidiabetic medications. Patients without multiple recorded mentions of an individual 
class of antidiabetic medications spanning more than 30 days post breast cancer diagnosis 
were parameterized as not having exposure to individual class of antidiabetic medications 
(n=25 for metformin). The resulting cohort contained female patients (n=1,180) with a 
median age of breast cancer diagnosis of 67 (34-95) years and median follow-up period 
of 83 (6-191) months.  A detailed diagram of cohort development can be found in Figure 
3.1 and a description of the cohort can be found in Table 3.1. Patients with metformin 
and fulvestrant exposure were silenced from analysis due to a small sample size (n=8) 
and unexpected effect on breast cancer specific mortality. Primary care patients 
represented 34.1% of the patients in the study cohort. Median age was similar between 
the primary care (68) and non-primary care (67) cohort, and similar number of metformin 
exposure events, 32.4% vs. 25.4% respectively. 
Figure 3.1: Cohort Development 
 
Table 3.1: Description of Cohort 
  event all 
Demographics 
  
all cause mortality 306 1188 
breast cancer-specific mortality 71 1053 
Unique cases of unilateral breast cancer  
(n = 35,341) 
New diagnosis of breast cancer in study 
period (01/01/1998 – 12/31/2011) 
(n = 13,163) 
Exclude male patients 
Attributable type 2 diabetes mellitus 
phenotype 
(n = 1,188) 
Exclude patients with T1DM or 
ambiguous diabetes status in EHR 
Exclude patients with known 
diagnosis of breast cancer 
(recurrent cases) prior to study 
period  
25 
follow up period 83 (6 , 191) 1188 
age at diagnosis of breast cancer 67 (34 , 95) 
1188 
 Age < 50 98 
 50>=Age<67 477 
 67>=Age<80 504 
 Age>=80 109 
resident of rural zip code 277 1162 
primary care patient 405  1188 
white 1072 1188 
Antidiabetic Therapies 
  
metformin 355 
1188 
insulin 245 
tzd 73 
sulfonylurea 182 
Diabetic Severity 
  
A1c   6.5 (4.5 , 15.1) 
687 uncontrolled diabetes 205 
BMI 
  
31.8 (14.5 , 
61.7) 
1135 
  
  
  
  
  
Underweight (BMI<18.5) 5 
Normal  (18.5>=BMI>25) 149 
Overweight (25>=BMI>30) 281 
Moderately obese 
(30>=BMI>35) 324 
Severely obese BMI>=35 376 
Breast Cancer Severity 
  
Stage In Situ 185 1152 
  
  
  
  
1 596 
2 14 
3 240 
4 25 
Grade 1 197 1188 
  
  
  
2 424 
3 273 
4 294 
Breast Cancer Receptor Status 
  
Estrogen Receptor Positive 795 919 
Progesterone Receptor Positive 728 893 
HER2/neu status actionable  925 925 
  HER2/neu positive 106 925 
Triple Negative 31 857 
Breast Cancer Treatment 
  
Surgery 444 979 
Chemotherapy 242 1174 
Radiation Therapy 227 890 
Hormone therapy 503 1168 
Immune therapy 12 1187 
Fulvestrant 43 1188 
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Aromatase inhibitors 567 1188 
Trastuzumab 96 1188 
Methotrexate 72 1188 
Ovarian oblation 23 1188 
Selective estrogen receptor modulators 918 1188 
Charlson Comorbidity Index 
  
Myocardial Infarction 73 
1188 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
Congestive heart failure 159 
peripheral vascular disease 132 
cerebrovascular disease 166 
Dementia 62 
chronic pulmonary disease 263 
ulcer 88 
mild liver disease 119 
diabetes 1188 
Diabetes with organ damage 206 
hemiplegia 20 
moderate/severe renal disease 135 
moderate/severe liver disease 24 
metastatic solid tumor 394 
Aids 0 
Rheumatologic disease 66 
Cancer 1188 
 Since clear clinical treatment progressions exist for T2DM (Inzucchi 2012) anti-
diabetic therapies carry implications for T2DM severity In order to isolate the effects of 
metformin and insulin beyond their impact on survival due to T2DM severity we engaged 
in a series of Cox Proportional Hazard Regression models. First, to identify separate 
baseline associations of metformin and insulin exposure on morality outcomes we 
developed separate univariate models. Second, to assess baseline additive associations for 
anti-diabetic therapies with morality outcomes we developed a multivariate model. Third, 
a stratified model was utilized to independently model the separate effects of anti-diabetic 
therapies on mortality outcomes (stratum 1) and breast cancer specific mortality (stratum 
2). Specifically, this stratified approach separately attributed the impact of anti-diabetic 
drug therapy on T2DM severity to stratum 1 and separately attributed the additional 
breast cancer-specific mortality burden on stratum 2. Stratification was utilized to control 
for covariates as opposed to a paired model to minimize potential unbalance in subgroup 
cohort size during the matching process. Since stratum 1 contained the impact of anti-
diabetic therapies on mortality outcomes we utilized its linear coefficient as an offset to 
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adjust for anti-diabetic drug therapy exposure associated with T2DM severity. Finally, 
we modeled the effect of metformin and insulin exposure, adjusted for T2DM severity on 
breast cancer specific mortality with breast cancer treatment and biology considerations. 
Exploratory interaction analysis was performed for both considerations. Backwards 
elimination was utilized to develop a final model of metformin and insulin exposure, 
adjusted for T2DM severity, for both considerations. Statistical analysis was performed 
using Linux SAS v9.3 and R 3.1.0. 
Results 
Baseline associations 
 Univariate survival analysis (Table 3.2a) demonstrated a protective baseline 
association of metformin exposure after breast cancer diagnosis with decreases in all 
cause mortality (HR=0.635,p-val=0.0049) and breast cancer-specific mortality 
(HR=0.293,p-val=0.0042). A detrimental baseline association for insulin exposure after 
breast cancer diagnosis with increases in all cause mortality (HR=2.124,p-val<0.0001) 
and breast cancer-specific mortality (HR=2.889,p-val<0.0001). Additive associations for 
metformin, insulin, and other anti-diabetic therapies (i.e. thiazolidinedione, sulfonylurea) 
demonstrated similar associations with morality outcomes (Table 3.2b). 
T2DM severity 
 The stratified model (Table 3.2c) identified a significant protective impact for 
metformin (HR=0.544 ,p-val=0.0017) and significant detrimental impact for insulin 
(HR=2.144, p-val<0.0001), controlling for other anti-diabetic therapies, on mortality 
outcomes in stratum 1. Due to the T2DM severity implications associated with T2DM 
therapy progression, these baseline associations were anticipated. The linear coefficients 
of stratum 1 were utilized as offsets in additional modeling on breast cancer outcomes 
Separately, the stratified model identified a significant protective association for 
metformin (HR=0.352, p-val=0.0273) and marginally significant detrimental association 
for insulin (HR=1.775, p-val=0.0772) on breast cancer specific mortality in stratum 2 that 
is beyond the impact of metformin and insulin on morality outcomes due to T2DM 
severity. Since stratum 2 did not control for confounding additive effects related to breast 
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cancer the impact of metformin and insulin on breast cancer outcomes was not 
representative. However, the directionality of these associations indicated decreases in 
baseline hazard ratios for both metformin and insulin.  
Table 3.2: Diabetes Medications 
 
Breast cancer treatment perspective 
 A full and reduced multivariate model of metformin, insulin, and breast cancer 
treatment, adjusting for T2DM severity can be found in Table 3.3. A backwards 
elimination model (not shown) evaluation potential interaction effects between 
metformin, insulin, and breast cancer treatments revealed no evidence of treatment 
interactions. The reduced model (Table 3.3b) identified a significant protective effect for 
metformin (HR=0.388, p-val=0.0353) and detrimental effect for insulin (HR=1.956, p-
val=0.0170) on breast cancer-specific mortality.  
 
 
Table 2a: Univariate Analysis of Metformin and Insulin 
  
  N 
All Cause Mortality  Breast Cancer-Specific Mortality 
HR p-val CI-low CI-high N HR p-val CI-low CI-high 
  
Metformin 330 0.635 0.0049 0.463 0.871 299 0.293 0.0042 0.127 0.679 
Insulin 219 2.124 <0.0001 1.608 2.806 197 2.889 <0.0001 1.712 4.876 
Table 2b: Multivariate model of T2DM medications 
  
  N 
All Cause Mortality  Breast Cancer-Specific Mortality 
HR p-val CI-low CI-high  HR p-val CI-low CI-high 
  
Metformin 330 0.628 0.0160 0.430 0.917 299 0.248 0.0003 0.117 0.527 
Insulin 219 2.119 <0.0001 1.499 2.996 197 3.190 <0.0001 1.848 5.506 
Thiazolidinedione 66 0.956 0.8866 0.514 1.777 58 2.163 0.0700 0.939 4.981 
Sulfonylurea 170 1.150 0.5388 0.737 1.794 157 1.458 0.2987 0.716 2.971 
Table 2c: Stratified T2DM Severity Model 
(Two baseline hazard ratios) 
  N HR p-val CI-low CI-high 
Strata 1: All Cause and Breast Cancer Specific Mortality 
  
Metformin 330 0.544 0.0017 0.372 0.795 
Insulin 219 2.144 <0.0001 1.515 3.034 
Thiazolidinedione 66 1.297 0.3139 0.782 2.150 
Sulfonylurea 170 1.283 0.1971 0.879 1.872 
Strata 2: Breast Cancer Specific Survival Endpoint 
  Metformin 299 0.352 0.0273 0.139 0.889 
  Insulin 197 1.775 0.0772 0.939 3.352 !
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Table 3.3: Breast Cancer Treatment Perspective, Adjusted for T2DM Severity 
Table 3.3a: Full Model Breast Cancer Specific Mortality 
N HR p-val CI-low CI-high 
  
Age 1046 0.552 0.0005 0.394 0.773 
Metformin 299 0.388 0.0356 0.161 0.938 
Insulin 197 1.944 0.0191 0.115 3.389 
Fulvestrant 24 5.177 <0.0001 2.456 10.910 
Aromatase inhibitors 513 0.815 0.4861 0.459 1.448 
Trastuzumab 83 1.427 0.3236 0.704 2.893 
Selective estrogen receptor 
modulators 838 0.616 0.0947 0.349 1.087 
Methotrexate 58 2.729 0.0022 1.437 5.184 
Chemotherapy 216 1.878 0.0298 1.064 3.316 
Table 3.3b: Reduced Model  HR p-val CI-low CI-high 
  
Age 1046 0.559 0.0008 0.398 0.786 
Metformin 299 0.388 0.0353 0.161 0.937 
Insulin 197 1.956 0.0170 1.127 3.394 
Fulvestrant 24 4.973 <0.0001 2.537 9.747 
Selective estrogen receptor 
modulators 838 0.578 0.0461 0.337 0.991 
Methotrexate 58 2.800 0.0017 1.475 5.315 
Chemotherapy 216 1.951 0.0158 1.133 3.358 
Breast cancer biology perspective 
 A full and reduced multivariate model of metformin, insulin, and breast cancer 
biology, adjusting for T2DM severity can be found in Table 3.4. A backwards 
elimination model (not shown) testing interaction effects between metformin, insulin, and 
breast cancer biology revealed no evidence of interactions by receptor status. However, it 
is important to note that clinical guidelines for testing overexpression of the relevant 
receptors has varied throughout the study period, having potential to bias these 
associations towards the null due to limited sample size and misattribution of receptor 
impact. The reduced model (Table 3.4b) identified a significant protective effect for 
metformin (HR=0.339, p-val=0. 0159), a detrimental effect for insulin (HR=2.201, p-
val=0.0131), and significant additive associations for estrogen receptor and HER2 on 
breast cancer-specific mortality.  
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Table 3.4: Breast Cancer Biology Perspective, Adjusted for T2DM Severity 
Table 3.4a: Full Model Breast Cancer Specific Mortality 
N HR p-val CI-low CI-high 
  
Age 1046 0.493 0.0003 0.337 0.723 
Metformin 299 0.344 0.0182 0.142 0.834 
Insulin 197 2.019 0.0310 1.066 3.824 
Progesterone receptor - positive 636 0.784 0.5879 0.325 1.891 
Estrogen receptor - positive 706 0.543 0.2114 0.209 1.414 
HER2 actionable - negative 394 2.217 0.0279 1.090 4.509 
HER2 actionable - positive 88 2.442 0.0535 0.987 6.045 
Table 3.4b: Reduced Model  HR p-val CI-low CI-high 
  
Age 1046 0.489 0.0001 0.339 0.703 
Metformin 299 0.339 0.0159 0.141 0.817 
Insulin 197 2.201 0.0131 1.181 4.101 
Estrogen receptor - positive 706 0.476 0.0366 0.237 0.955 
HER2 actionable - negative 394 2.425 0.0107 1.231 4.886 
HER2 actionable - positive 88 2.434 0.0451 1.020 5.811 
Patient demographic considerations 
Table 3.5: Patient Demographics 
 
Table 3.5: 
Demographics 
All Cause Mortality Breast Cancer-Specific Mortality 
HR p-val 
CI -
low 
CI - 
high HR p-val 
CI -
low 
CI - 
high 
  
Metformin 0.625 0.0039 0.454 0.860 0.433 0.0218 0.212 0.885 
Insulin 1.807 0.0001 1.338 2.441 2.587 0.0009 1.475 4.538 
Age < 50 ref ref ref ref ref ref ref ref 
50>=Age<67 0.879 0.6181 0.530 1.459 0.368 0.0107 0.171 0.793 
67>=Age<80 1.586 0.0630 0.975 2.579 0.612 0.1699 0.304 1.234 
Age>=80 3.983 <0.0001 2.324 6.828 0.951 0.9167 0.371 2.435 
White 0.756 0.1954 0.495 1.154 0.796 0.5679 0.363 1.744 
Rural 
residence 1.307 0.0415 1.010 1.690 0.966 0.9048 0.548 1.703 
BMI (>= 35) 1.043 0.7547 0.799 1.362 0.743 0.2915 0.427 1.291 
Charlson 
Score > 8 2.475 <0.0001 1.952 3.139 8.713 <0.0001 4.773 15.906 
 Postmenopausal women with a diagnosis of breast cancer at < 67 years old were 
associated with decreased breast cancer specific mortality (HR=0.368, p-val=0.0107) 
when compared to premenopausal women. Surprisingly, obesity (BMI>=35) was not 
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significantly associated with either all cause or breast cancer specific mortality outcomes 
(Table 3.5) since obesity is associated with both increased diabetes and breast cancer 
incidence. However, the majority (61.7%) of patients in this study cohort were obese 
(Table 3.1). Rural residence was selected for inclusion in the final due to a significant 
overall association (HR=1.307, p-val=0.0415) between rural patient residence and overall 
survival. 
Discussion 
 Existing literature evaluating the associations of metformin exposure occurring 
after breast cancer incidence with mortality outcomes have yielded inconclusive and 
inconsistent results (Zhang 2014, Lega 2014). Cohorts have been heterogeneous (Lega 
2014), definitions of metformin exposure have varied (Lega 2014), and methodological 
approaches to approach for confounding have varied (Lega 2014). Further, studies not 
utilizing breast cancer specific morality as an endpoint (Hou 2013, Xiao 2014, Bayraktar 
2012, Currie 2012, Xu 2014) are critically limited in their ability to elucidate the impact 
of metformin and insulin on mortality that is beyond that which is due to T2DM severity. 
Our study added clarity to these studies by evaluating metformin exposure occurring after 
breast cancer diagnosis and addressing robust indicators including breast cancer receptor 
status and breast cancer-specific mortality not available in previous studies. Further, our 
analysis efforts independently isolated the effects of metformin and insulin due to 
implications for T2DM severity and their impact on breast cancer mortality outcomes. In 
this study, we consistently identified a significant protective effect for metformin and 
significant detrimental effect for insulin on breast cancer-specific mortality that is beyond 
their impact on T2DM severity.  
 This study is uniquely poised to elucidate the impact of metformin and insulin 
exposure on morality outcomes that is due to their effect on breast cancer mortality 
outcomes during breast cancer treatment and not due to the effect T2DM severity 
associated with the original purpose of metformin and insulin as a T2DM treatment 
regiment. We are further advantaged in our ability to include robust structured (Chute 
2010), semi-structured (Pathak 2011), and unstructured (Savona 2010) clinical and 
treatment indicators not commonly available in population or claims-based studies. These 
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approaches afford independence from manual chart review for cohort ascertainment and 
are highly granular but also highly portable and scalable. Finally, we are uniquely poised 
to perform future translation biomedical research on parallel subcohorts due to the large 
percentage of patients who have donated, plasma, serum, and tumor samples for research 
to biobanks. 
 A limitation for this study includes lacking insight into duration of metformin and 
insulin treatment prior to breast cancer treatment for referral patients (n=783) due to 
incomplete historical clinical data. While, the efforts of isolating the confounding 
relationship between T2DM severity and T2DM treatment remove this limitation for 
exposure occurring during breast cancer treatment, we are unable to evaluate the potential 
modifying impact of metformin and insulin duration of exposure occurring prior to breast 
cancer treatment on breast cancer incidence and severity. Further, an estimated 
approximately 30% of patients do not respond to metformin (Cook 2007), necessitating 
alternative anti-diabetic therapy. Due to incomplete historical data we were not able to 
account for a potential difference between patients that did not respond to metformin 
treatment prior to breast cancer treatment. Finally, disease-specific cause of death could 
not be ascertained for 44.1% (n=135) of eligible patients with known mortality events 
(n=306) due to deaths occurring outside of MN, which has potential to skew 
interpretation of disease-specific survival analysis towards the null. Median follow-up 
period was similar amongst patients with known mortality (61.5 months) vs. patients with 
known mortality but missing cause of death (65.0 months).  
 As research on the potential repurposing of metformin in breast cancer proceeds 
forward it is important to note that the biological function and mechanism of metformin 
remains unclear (Todd 2014). The pharmacokinetics (PK) of metformin, the 
transportation throughout the body, are moderately understood (Gong 2012). Metformin 
is not metabolized, with absorption of metformin known to occur in the small and large 
intestine (Graham 2011). Uptake of metformin from the blood is known to occur in the 
kidneys and liver (Todd 2014), but can be reasonably assumed to occur in any tissue with 
abundance of organic cation transporters (OCT)(Viollet 2012). Eventually metformin is 
excreted unchanged in the urine(Graham 2011). However, the pharmacodynamics (PD) 
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of metformin, the physiological and biochemical impact of metformin in the body, are 
not clearly understood(Gong 2012). Metformin works primarily by inhibiting hepatic 
glucose production by reducing gluconeogenesis in the liver (Hundal 2000) and is also 
known to reduce intestinal glucose absorption(Sakar 2010). Further, metformin appears 
to improve glucose uptake and utilization systemically (Gong 2012). However, there is 
considerable variation in glycemic response to metformin(Gong 2012) and serious 
adverse reactions to metformin can occur (Bailey 1996). Further, an important 
confounding factor to consider based on in vitro models is that ‘metformin is probably 
unable to exert cytotoxic or cytostatic effects on breast cancer subtypes at 
pharmacological concentrations and normal plasma glucose levels’ (Sadighi 2014), 
suggesting that the effect of metformin on breast cancer is more complex than 
cytotoxicity. Further research integrating multi-omics approaches to elucidate the 
biological function and mechanism of metformin in breast cancer is needed.  
Conclusion 
 Metformin exposure during the treatment period after breast cancer diagnosis 
demonstrated a significant protective effect on breast cancer-specific mortality, while 
insulin during the same period demonstrated a significant detrimental effect. Our study 
demonstrates that the strength of these effects is beyond their implications for T2DM 
severity. 
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Part #2: Accounting for Socioecological Context in Translational Research 
Due to the confounding relationship between clinical and social factors it is likely that 
the effect of socio-ecological conditions (SECs) is being inappropriately attributed to 
clinical variables in retrospective clinical research. Utilizing validated measures of 
social stress as the SEC of interest and Charlson Comorbidity Index as the training 
outcome I created a SEC Index that aimed to capture direct and latent community effects 
surrounding social stress. While not a perfect solution, I demonstrated a potential 
approach to incorporate SEC into clinical research models that minimizes power loss 
and model over fitting. 
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Chapter 4: Studying the Confounding Effects of Socio-Ecological Conditions in 
Retrospective Clinical Research: A Use Case of Social Stress 
Abstract 
 Socio-ecological Conditions (SECs) are important to include in clinical research 
models as they have been known to impact the health of patients. However, current 
clinical research models account for these factors only in an unsatisfyingly rudimentary 
way. In this study, I developed an SEC Index that captured the latent and direct effects of 
social stress, one of the many kinds of SEC, on patients’ general health as measured by 
the Charlson Comorbidity Index. I demonstrated that the above SEC Index had a 
significant effect in a clinical model, a patient-level model with the specific clinical 
outcome of breast cancer prevalence. Further, I demonstrated that including the SEC 
Index of social stress into the clinical models significantly increased their performance. 
This study demonstrated a viable approach that is interchangeable to include any SEC of 
interest, to more appropriately account for SECs in clinical research models. 
Introduction  
 Socio-ecological Conditions (SECs) have been known to impact the health of 
patients, but current clinical research models account for these factors only in an 
unsatisfyingly rudimentary way. Phenomena such as access to health care and social 
support networks are examples of SEC; factors that can profoundly impact a patient’s 
health and prognosis once health deteriorates. SECs not only influence outcomes, but 
they confound patient characteristics and clinical factors, inhibiting the ability of clinical 
models to estimate the effect of clinical factors independently of SECs. Specifically, 
without adjusting for SECs we can only estimate the combined effect of SEC and the 
clinical factors.  
 In what follows, we describe SECs in more details, present our methodology and 
demonstrate its utility on a large tertiary care provider in the Midwest U.S. In this study, 
we set out to develop an SEC Index, a summary of socio-ecological measures that 
quantifies the effect of SECs on patients’ general health. Then we utilize this SEC Index 
in a clinical risk prediction model with a specific end point (e.g. breast cancer prevalence) 
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and show how the inclusion of the SEC Index results in a statistically significantly better 
model. 
Background 
 Socio-ecological conditions (SECs) are the embodiment of social and ecological 
population factors that exist within a defined geographical region (i.e. community) and 
are known to impact health of an individual patient1 and enhance stability of retrospective 
clinical research2. A community is an amalgamation of social interactions and 
geographical proximity exhibiting many confounded and latent characteristics. These 
characteristics cannot be effectively measured as independent metrics, and are known to 
vary across geographic regions1. While person-level measurements of socioeconomic 
status are commonly included in statistical analysis in an attempt to control for alternative 
confounding factors, they do not adequately represent the underlying phenomena at the 
root of an SEC4. Further, placing measures of SEC directly in models can lead to model 
overfitting and potentially reduces power. In our study we chose to focus on the SEC 
mechanism social stress because of its hypothesized relevance to breast cancer and 
because it has established, validated population measures. However, it is most important 
to emphasize that any SEC phenomenon of interest, such as factors measuring social 
contagions, demographic change, and social capital, can be readily substituted within the 
study design.  
 Social stress is a phenomenon experienced by individuals when they do not have 
the resources to address an acute situation4. Further, social stress is known to be highly 
confounded with socioeconomic status (SES)4. Social stress has been associated with 
negative impacts on health, including increased prevalence of asthma, diabetes, 
gastrointestinal disorders, myocardial infarction, cancer, and rheumatoid arthritis5. Social 
stressors are commonly socially patterned, and can manifest at both the individual and 
community level6. Further, mouse models of social stress have identified correlations 
between localized (i.e. non-systemic) mammary adipose-specific metabolic changes and 
increased mammary tumor growth7.  
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 We chose to use validated measures of social stress: Index of Dissimilarity(D-
score)8, Townsend Index of Socioeconomic Derivation Index(T-score)9, and poverty4. 
For brevity, we omit the exact definitions, but at a high level, D-score quantifies 
the homogenization of racial distribution across geographic areas in relation to the entire 
geographic region of study; and T-score, which is composed of four components, 
measures unemployment, non-car ownership, household overcrowding, and non-home 
ownership. Poverty is a measure collected and provided by the US Census Bureau and 
provides a direct measures of socioeconomic deprivation.  
Study Aim 
 In this work, we seek to understand if variation in established measures of socio-
ecological conditions (SEC) for social stress are associated with breast cancer prevalence. 
Specifically, we developed an SEC Index using the above validated SEC measures of 
social stress; and later used this index as a covariate in addition to patient-level clinical 
covariates in a model predicting breast cancer prevalence (clinical model)  
Materials  
 This study utilizes a combination of clinical and population-based data sources. A 
cohort consisting of primary care patients (n=228,069) with longitudinal clinical data 
were aggregated from Mayo Clinic’s EHR and Enterprise Data Trust10 using a 
combination of structured queries. Validated population measures of social stress were 
calculated using 2010 American Community Survey and US Census datasets. All 
population data was clustered at the census block group level. A SAS address–census 
block group crosswalk (proc geocode) was used to assign patients to their Census Block 
Group (CBG) of residence. CBGs (n=278) corresponding to Mayo Clinic’s (in Rochester, 
Minnesota, USA) primary care coverage area (Dodge, Fillmore, Goodhue, Houston, 
Mower, Olmsted, Wabasha, and Winona Counties in Minnesota, USA) were included in 
the analysis. Patients who had designated residence in more than one CBG corresponding 
to Mayo Clinic’s primary care coverage area were excluded from this study. Further, to 
eliminate estimation bias in low coverage areas patients who resided in census block 
groups with <50 patients were excluded from this study. CBGs were assigned a random 
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identifier and patient-level data was de-identified prior to analysis to ensure patient 
privacy and confidentiality. The final analysis cohort contained deidentified data for a 
relatively homogeneous cohort of 94,561 patients and 237 CBGs. A detailed diagram of  
cohort demographics can be found in Table 4.1.  
Table 4.1: Cohort Demographics  
(n=94,561) 
Age 
  
>=18 to ≤25 14,583 15.4% 
>25 to ≤35 16,761 17.7% 
>35 to ≤45 16,262 17.2% 
>45 to ≤55 18,160 19.2% 
>55 to ≤65 11,793 12.5% 
>65 to ≤75 8,393 8.9% 
>75 to ≤85 6,143 6.5% 
>85 2,466 2.6% 
Caucasian 85,238 90.1% 
Male 43,833 46.4% 
Coverage  
  
Low (<33%) 17,939 19.0% 
Medium (33 to 
50%) 18,893 20.0% 
High (50 to 
100%) 57,729 61.0% 
Poverty 6,720 7.1% 
T-score 
  
High 
Unemployment 15,440 16.3% 
  
High Non-Car 
Ownership 6,720 7.1% 
D-Score High 9,323 9.9% 
Methods 
 Our proposed method has two steps.  First, we develop the SEC Index using a 
generic endpoint to quantify the effect of the SEC measures on health in general. For this 
step, we utilize 30% of the data set.  In the second step, we utilize the remaining 70% of 
the data and build the specific clinical model, which includes the SEC Index as an 
independent variable, with breast cancer prevalence as the clinical end point. Note that to 
avoid model overfitting, the portion of the data (30%) on which the SEC Index is 
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developed has no overlap with the portion of the data (70%) that the clinical model is 
constructed on.  
SEC Index Construction 
 We construct an SEC Index to capture the effect of a number of known measures of 
social stress on the patients’ general health. We quantify patients’ general health through 
the Charlson Comorbidity Index11, with index value in excess of 3 indicating high risk of 
mortality (poor health). The independent variables include the D-score8 (averaged over 
each census block group and dichotomized12 into high and low at .5), components of the 
T-score9, poverty13, rurality14, and coverage. The D-score quantifies homogenization of 
racial distribution across geographic areas in relation to the entire geographic region of 
study. CBG poverty is defined as absolute poverty thresholds, a measured and defined by 
the US Census Bureau13. In our study, D-score was calculated for individual patients 
(stratified at 90th percentile) and then averaged within each census block group. T-score 
was measured by unemployment (90th percentile), non-car ownership (20th percentile), 
household overcrowding (10th percentile), and non-home ownership (90th percentile). 
Poverty was stratified at the 90th percentile. Coverage was defined as the percentage of 
the population in the CBG who received their primary care at Mayo Clinic. Coverage 
needs to be adjusted for, as patients in certain CBGs only receive specialty care (such as 
breast cancer treatment) from Mayo Clinic, falsely suggesting that those regions have 
people who are disproportionally sick or with better access. The independent variables in 
the SEC Index are not patient-level variables; they are aggregated to CBG-level as they 
are aimed to capture CBG-level effects. The SEC Index itself is a binomial propensity 
score model and the index score is the link-space (linear) prediction from this model. 
Applying the SEC Index 
 To show the effectiveness of the SEC Index, we develop two breast cancer 
prevalence models on the remaining 70% of the cohort. The first model, our baseline, 
contained patient measures of age and gender and did not utilize the SEC Index; the 
second model contained age, gender, and our trained SEC Index. Both models were 
logistic regression models. 
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Evaluation 
 We used concordance as the metric of model performance. For a randomly selected 
pair of patients, with exactly one of the two having breast cancer, concordance is the 
probability that the predicted risk of breast cancer is higher for the breast cancer patient 
than for the one without breast cancer. Concordance is also known as C-statistic or Area 
under the ROC curve (AUC). 100 replications of bootstrap simulation were used to 
estimate the model performance for the two clinical models.  
 In bootstrapping, a simulated data set of the same size as the original is created by 
sampling the patients of the original data set with replacement. As a result of sampling 
with replacement, some of the original patients are excluded from the simulated data set 
and others are included multiple times. The patients excluded are referred to as “out-of-
bag” patients and are set aside for validation. In each of the 100 replications, the SEC 
Index model was constructed (on 30% of the simulated data set) and the two clinical 
models (one with and one without the SEC Index) were developed on the remaining 70% 
of the simulated data set as described above. The concordance for the two clinical models 
was calculated on the out-of-bag (validation) patients. After the 100 replications, we had 
100 SEC Index models and 100 pairs of clinical models with 100 pairs of concordance 
values. A paired t-test was utilized to compare the 100 pairs of concordance measures.  
Results 
 We first present the overall results of the bootstrap simulation. Finally, to offer 
further insight into our methodology, we also present the SEC Index model and the 
clinical model of a specific replication. 
Bootstrap Simulation 
 Overall, the model for breast cancer prevalence that included the SEC Index in 
addition clinical characteristics for age and gender in bootstrap replications (n=100) 
performed strongly significantly (t=5.8457,p=6.489x10-8) better than the model without 
the SEC Index, indicating that the inclusion of the SEC Index is significantly beneficial 
to the model performance. Further, in 22% of the individual bootstrap replications, the 
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SEC variable was designated as a statistically significant predictor of breast cancer 
prevalence. 
Table 4.2: Propensity Training Model 
Variable Estimate Standard Error Z Test P-value 
Intercept -1.8026 0.0225 -79.975 < 2e-16 
Poverty 0.0943 0.0381 2.478 0.0132 
T-score 
 
 
V1 -0.1303 0.0284 -4.595 4.32e-06 
V2 0.1914 0.0643 2.978 0.0029 
Coverage 
 
 
33 to 50% 
(vs. <33%) -0.1230 0.0305 -4.034 5.48e-05 
50 to 100% 
(vs. <33%) -0.2765 0.0254 10.883 < 2e-16 
D-Score 0.1971 0.0316 6.248 4.16E-10 
Specific Example 
 We randomly chose 1 of the 22 bootstrap models where the trained SEC Index 
demonstrated a significant impact on breast cancer prevalence measures (Table 4.2). This 
model included measures for poverty, coverage, T-Score (unemployment and non-car 
ownership), and D-Score. Census block groups with high social stress SEC demonstrated 
a significant (p=0.0168) detrimental (Beta=0.2948) effect (Table 4.3).  
Table 4.3: Demonstration of SEC 
Variable Estimate Standard Error Z Test P-value 
Intercept -5.7700 0.3562 -16.197 < 2e-16 
Age (years), baseline: ≥18 to ≤25 
 
 
 
 
 
 
 
>25 to ≤35 1.6063 0.2809 5.719 1.07e-08 
>35 to ≤45 2.7252 0.2665 10.225 < 2e-16 
>45 to ≤55 3.4421 0.2622 13.130 < 2e-16 
>55 to ≤65 4.0885 0.2617 15.624 < 2e-16 
>65 to ≤75 4.5772 0.2615 17.501 < 2e-16 
>75 to ≤85 4.5463 0.2626 17.316 < 2e-16 
>85 4.5198 0.2676 16.889 < 2e-16 
Male -2.3522 0.0676 -34.786 < 2e-16 
SEC 0.2948 0.1233 2.391 0.0168 
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Discussion  
 We have demonstrated that the use of an SEC Index for social stress significantly 
increased the performance for prediction of breast cancer prevalence even in our study 
region located in the Upper Midwest, where differences among CBGs in terms of SEC 
are relatively modest. We expect the impact of using the SEC Index to amplify when 
applied to a region where SEC differences among regions are more pronounced. We wish 
to emphasize that the purpose of this study is neither to recommend the use of specific 
SEC measures nor to quantify a neighborhood effect, which has been proven theoretically 
impossible15. Rather, our intent is to better identify clinical effect, which our method 
successfully accomplished. 
Strengths and Limitations 
 Our proposed method offers significant benefits. The most important benefit is that 
it helps separate the effect of SECs from the effect of clinical variables: without 
accounting for SEC, we would have only been able to measure the combined effect of the 
clinical variables and SEC; accounting for SEC helped elucidate the true effect of the 
clinical variables. SEC measures are so highly correlated with each other that efforts to 
separate their effect has been deemed fruitless15. Including the individual SEC measures 
into a clinical model would make overfitting inevitable and would limit degrees of 
freedom, while including the SEC Index contains the collinearity problem of the SEC 
measures in the SEC Index model. Further, being able to capture the effect of SEC 
through the patients’ generic health (as measured by the Charlson Comorbidity Index) 
and being able to use it for a specific clinical end point (breast cancer prevalence) enables 
large-scale generalizability across organizations and coverage areas. The (arguably 
imperfect) separation between SECs and the clinical variables that the SEC Index affords 
helps capture the differences in SECs between organizations and coverage areas, leading 
to more accurate estimates for the clinical effects. Finally, the proposed methodology also 
allows us to incorporate additional validated or new measures of SEC that may help 
better separate the impact of SECs and patient characteristics. The SEC measures used in 
this study are merely a sample of the measures in existence. Alternative measures of 
interest, for example social contagions, demographic change, and social capital, can be 
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incorporated into the SEC Index in a straightforward way without causing the clinical 
model to overfit the data. 
Future Work 
 Despite medicine’s rigorous pace of advancement, appropriately capturing SEC 
patterning of disease remains an important topic. With the advent of harnessing social 
media data and focus on consumer health informatics it is important to consider the 
lingering issue of how we can quantify the effect of SEC using relatively stable 
population-based data through validated measures. Advancing our understanding and 
utilization of SECs is necessary to advance our understanding of the complex, 
multifactorial causes of cancer16.  
Conclusion  
 This study demonstrates a viable approach to account for SECs, including social 
stress, in retrospective clinical research. An important distinction exists between the 
utilization of SECs to control for confounding effects in retrospective research and 
utilizations in population health or clinical decision support, critical considerations 
remains in how to accurately address the long-standing concerns of social epidemiology 
in consumer health informatics. 
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Part #3: Leveraging the Electronic Health Record(EHR)-Linked Biorepository in 
Translational Bioinformatics 
While metformin is generally well tolerated approximately 30% of patients do not 
respond to metformin with some patients having adverse reactions. The 
pharmacogenomics of metformin are not clearly understood; it is imperative to 
understand molecular mechanisms of metformin further. In this part I sought to explore 
genetic variation that is responsible for glycemic response to metformin.  
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Chapter 5: The Impact of Genomic Variation on Glycemic Response to Metformin 
Using EHR-Linked Biorepository Data.  
Abstract 
Metformin is a first-line antihyperglycemic agent commonly prescribed in type 2 diabetes 
mellitus (T2DM), but whose pharmacogenomics are not clearly understood. Due to the 
epidemic growth of T2DM in the US and the accumulating evidence highlighting 
potential repurposing of metformin for cancer prevention and treatment it is imperative 
to understand molecular mechanisms of metformin further. In this pharmacogenomics 
study we seek to identify potential personalized medicine targets that are associated with 
response to metformin treatment. Specifically, we seek to elucidate the impact of key 
genetic variants that modify glycemic response to metformin treatment. Seventeen genes 
with suspected pharmacokinetic or pharmacodynamic implications were selected based 
on systematic review for study. Our analysis cohort consisted of 258 T2DM patients who 
had new metformin exposure, existing genomic data, and longitudinal electronic health 
records. Change in glycemic response to metformin exposure via A1c measures pre and 
post metformin exposure serve as the outcome of interest. After quality control, gene-
level and SNP-level analysis were conducted on 17 candidate genes and 463 SNPs within 
those genes was performed, controlling for key covariates of sex, age, and body mass 
index (BMI) at index metformin exposure. PRKAB2, the gene encoding the beta subunit 2 
of adenosine monophosphate-activated protein kinase complex, is associated with 
significant (p=0.0194) change in glycemic response after exposure to metformin. 
SLC29A4, the gene encoding the plasma membrane monoamine transporter expressed in 
the intestine, the next most significant gene (p=0.0614), has potential to also be 
associated with glycemic response after exposure to metformin. This study serves as an 
example of how EHR-linked biorepositories can be used to test pharmacogenomics 
hypotheses using intermediary clinical phenotypes.  
1.  Background 
 Metformin is recommended as a first-line therapy for type 2 diabetes mellitus 
(T2DM)[1] and is believed to be the most prescribed drug worldwide[2]. Evidence is also 
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accumulating that highlights the potential repurposing of metformin for cancer prevention 
and treatment[3]. However, the details underlying the molecular mechanism of action for 
metformin are not fully understood[2]. It is imperative to understand the molecular 
mechanisms of metformin further, particularly genetic variation in clinically relevant 
targets of metformin [4]. 
 Metformin is in the biguanides class of medications and is primarily utilized to 
regain glycemic control in diabetic or pre-diabetic patients. Metformin is a relatively safe 
antidiabetic therapy[5]. However, serious adverse reactions can occur[6]. The 
pharmacokinetics (PK) of metformin, the transportation throughout the body, are 
moderately understood[7]. Metformin is not metabolized, with absorption of metformin 
known to occur in the small and large intestines[5]. Uptake of metformin from the blood 
is known to occur in the kidneys and liver[2], but can be reasonably assumed to occur in 
any tissue with abundance of organic cation transporters (OCT)[8]. Eventually metformin 
is excreted unchanged in the urine[5]. However, the pharmacodynamics (PD) of 
metformin, the physiological and biochemical impact of metformin in the body, are not 
clearly understood[7]. Metformin works primarily by inhibiting hepatic glucose 
production by reducing gluconeogenesis in the liver[9] and is also known to reduce 
intestinal glucose absorption[10]. Further, metformin appears to improve glucose uptake 
and utilization systemically[7]. However, there is considerable variation in glycemic 
response to metformin[7]. While genetic factors may partially explain glycemic response 
to metformin, further studies are needed to understand the impact of variation in key 
transporter genes on glycemic response in clinical populations[2]. 
 Our study aims to add clarity to metformin pharmacogenomics by understanding 
the impact of common variants in metformin candidate genes (n=17) on altered glycemic 
response in a clinical population. Candidate genes selected for inclusion in this study are 
suspected metformin PK or PD determinants as designated in systematic reviews of 
metformin pharmacogenomics[2,5,7,8,11]. Gene-level and SNP-level analyses were 
performed in this study to identify genes significantly associated with change in glycemic 
response after exposure to metformin and directionality of the effect of corresponding 
SNPs. 
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2.  Materials and Methods 
 In order to elucidate a pharmacogenomic perspective on glycemic response to 
metformin, all patients selected for inclusion into this study have known exposure to 
metformin and T2DM (n=258) with corresponding glycemic cross sections. 
2.1.  Materials 
 All genomic data utilized in this study was a part of a local biorepository with 
linked longitudinal electronic health record data[12]. Patients with existing GWAS data, 
T2DM, known metformin exposure, and longitudinal glycemic indicators were included 
in this study. Patients without known metformin exposure >= 6 months, without A1c 
measures >=6 months apart prior to and concurrent with the metformin exposure, and 
without genomic data with >=95% call rate within candidate genes were excluded from 
this study. Clinical phenotypes were developed using EHR-based algorithms and data. A 
final cohort of Caucasian patients (n=258) with known metformin exposure, T2DM, 
longitudinal A1c measures, and genomic data with >= 95% call rate was utilized in this 
study. A description of the cohort is found in Table 5.1 and a detailed diagram of cohort 
development is found in Figure 5.1. 
Table 5.1: Cohort Demographics 
 n      (%) 
Female 89    (34.5) 
Male 169  (64.5) 
BMI < 30 64    (24.8) 
BMI >= 30 
to < 35 100  (38.8) 
BMI >=35 93    (36.1) 
Median A1c 
> 7.0 101  (39.1) 
  Median Range 
Change in 
A1c 0.0733 -6.45 3.51 
Age 64 30 84 
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Figure 5.1: Cohort Development 
 
2.2.  Methods 
 17 candidate genes suspected to be determinants of metformin PK or PD were 
selected for inclusion in this study based on suspected relevance in recent systematic 
reviews[2,5,7,8,11] (Table 5.2).  
 Attribution of a T2DM phenotype was performed using modified methodology 
developed by eMERGE [13]. Metformin exposure was ascertained using a combination 
of validated structured[14] and semi-structured[15] EHR data collection methodologies. 
To compare the genetic modification of glycemic response to metformin, measures of 
A1c were compared prior to metformin exposure and during the period of metformin 
exposure following a 6-month period of delay. In this study, A1c was calculated as the 
difference between the average of A1c measures within 6 months prior to metformin 
exposure and the average of A1c measures between >= 6 months after exposure to 
Biorepository patients 
(n = 42,884) 
Type 2 diabetes mellitus patients 
(n = 5,980) 
Include patients with attributable 
T2DM phenotype 
Known metformin exposure 
(n = 3,763) 
Exclude patients with no known 
metformin exposure 
Exclude patients lacking 
longitudinal EHR data, or enrolling 
in biorepository after 5/1/2014 
Existing GWAS data 
(n = 285) 
Cross sectional glycemic data available 
(n = 1,793) 
Exclude patients without existing 
genomic data 
Final Cohort 
(n = 258) 
Exclude patients with < 95% call 
rate for SNPs within target genes 
Exclude patients without A1C 
measures before metformin 
exposure and >=6 months to end of 
metformin therapy exposure 
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metformin and the end of metformin exposure. This approach minimizes the impact of 
any one A1c measure and biases change in A1c measures towards the null. Age, gender, 
and morbid obesity (BMI >= 35), a known modifier of T2DM state[1], were selected for 
inclusion as covariates in the model. Age and BMI measures were calculated at first 
recorded exposure to metformin.  
Table 5.2: Candidate Genes  
PGX Gene Name 
Chromo-
some 
SNP 
counts 
Protein 
Name Protein Full Name 
PK SLC22A1 6 38 OCT1 organic cation transporter 1 
PK SLC22A2 6 31 OCT2 organic cation transporter 2 
PK SLC22A3 6 33 OCT3 organic cation transporter 3 
PK SLC29A4 7 13 PMAT plasma membrane monoamine transporter 
PK SLC47A1 17 19 MATE1 multidrug and toxin extrusion protein 1 
PK SLC47A2 17 20 MATE2-K multidrug and toxin extrusion protein 2 
PD 
Adenosine monophosphate-activated protein kinase (AMPK) complex 
 
PRKAA1 5 19 AMPK-A1 AMPK-alpha subunit 1 
PRKAA2 1 24 AMPK-A2 AMPK-alpha subunit 2 
PRKAB1 12 13 AMPK-B1 AMPK-beta subunit 1 
PRKAB2 1 35 AMPK-B2 AMPK-beta subunit 2 
PRKAG1 12 8 AMPK-G1 AMPK-gamma subunit 1 
PRKAG2 7 132 AMPK-G2 AMPK-gamma subunit 2 
PRKAG3 2 9  AMPK-G3 AMPK-gamma subunit 3 
PD STK11 19 10 LKB1 liver kinase B 
PD PPARG 3 42 PPARG peroxisome proliferator-activate receptor gamma 
PD ATM 11 13 ATM ataxia telangiectasia mutated serine/threonine protein kinase 
PD GCKR 2 14 GCKR glucokinase regulatory protein 
PGX = pharmacogenomic implication, PK = Pharmacokinetics,  
PD = Pharmacodynamics 
2.2.1.  Quality Control 
 For the 17 candidate genes, we selected SNPs 50 kb upstream and downstream of 
each gene using 1000 genomes project variants and NCBI build 37 as the reference 
genome. By this mapping rule, a total of 8440 SNPs were mapped to the 17 genes, but 
only 1065 SNPs were available in the genotype data. For the remaining SNPs, two main 
quality control filters were applied: (i) SNPs with unacceptable high rates of missing 
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genotype calls (>10%); and (ii) monomorphic SNPs were excluded. The quality control 
of the genotype data was performed by PLINK v 1.07[16]. The call rate was < 0.90 for 
601 SNPs and 1 SNP was monomorphic, leaving 463 SNPs for the single SNP and gene-
level analyses. From the total of 285 samples with available genotype, we excluded 27 
samples with call rate < 0.95, leaving 258 samples available for analysis in the final 
cohort. 
2.2.2.  Gene-Level Analysis Method 
 We analyzed the association of each gene with the change in a1c using Van der 
Waerden rank, or rank based inverse Gaussian, transformed change in A1c. Gene level 
tests were performed using principal component analysis (PCA) as described 
previously[17]. For each gene, principal components were created using linear 
combinations of ordinally scaled SNPs (i.e., 0, 1, 2 copies of minor allele) and the 
smallest set of resulting principal components that explained at least 90% of the SNP 
variance was included in linear regression models. Instead of including the entire set of 
SNPs for each gene, the principal component approach reduces the degrees of freedom, 
avoids model fitting issues due to multi-collinearity of the SNPs from linkage 
disequilibrium (LD) and potentially improves the statistical power. Finally, to assess 
overall significance of a gene, we computed the likelihood ratio test (LRT) by comparing 
the null model containing only the covariates with the full model containing covariates 
and the set of resulting principal components. At the gene-level, results of the 17 
simultaneous hypothesis tests were utilized for filtering. Plots of LD displaying r2 for 
each gene based on 258 Caucasian samples were created using Haploview v 4.2. The 
statistical package R 2.15.0 was used for the gene-level analysis[18]. 
2.2.3.  SNP-Level Analysis Methods 
 We tested the association between each SNP and Van der Waerden rank 
transformed change in A1c using a linear regression model, adjusting for age, gender and 
morbid obesity. Coefficient estimates were calculated per minor allele, that is, with each 
minor allele, the A1c level changes by ‘beta’. SNP-level results were not corrected for 
multiple testing. 
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3.  Results 
 A series of analyses were performed to elucidate the potential modifying impact of 
common variants in candidate genes on glycemic response to metformin. First, a gene-
level analysis was performed to identify genes significantly associated with change in 
glycemic response after exposure to metformin (Section 3.1). Since this gene-level 
analysis was based on principal components having undetermined signs they are unable 
to indicate directionality, requiring additional SNP-level analysis. The SNP-level analysis 
was performed on significant and marginally significant candidate genes identified in 
Section 3.1 to confirm and determine directionality of these associations (Section 3.2). 
Finally, an exploratory SNP-level analysis was conducted to identify potential SNP-level 
associations in non-significant candidate genes (Section 3.3). 
3.1.  Gene-Level Results 
 The estimates for male (Coef=0.04,P-val=0.737), age (Coef=-0.0009,P-val=0.881), 
morbid obesity (Coef=0.22,P-val=0.083) were not significantly associated with change in 
A1c at alpha=0.05 significance level. In the multivariate model, none of the covariates 
were associated with change in A1c at alpha=0.05 significance level.  
Table 5.3: Principal Component (PC) Analysis 
Gene Name nSNPs nPCs P-value 
PRKAB2 35 5 0.0194 
SLC29A4 13 9 0.0614 
PRKAG1 8 4 0.1548 
SLC47A1 19 7 0.2121 
GCKR 14 4 0.2365 
SLC47A2 20 5 0.3237 
STK11 10 8 0.4450 
PRKAA1 19 6 0.5104 
ATM 13 5 0.5256 
PRKAA2 24 12 0.5439 
SLC22A3 33 6 0.6017 
PPARG 42 13 0.7499 
PRKAB1 13 4 0.7665 
PRKAG3 9 6 0.8113 
PRKAG2 132 46 0.8292 
SLC22A1 38 12 0.8487 
SLC22A2 31 8 0.9086 
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 After controlling for age, gender, and morbid obesity the PCs for the 17 candidate 
genes capturing 90% of the summed variation in SNPs identified 1 candidate gene as 
being significantly associated with glycemic response. PRKAB2, the beta subunit 2 of 
adenosine monophosphate-activated protein kinase complex, represented by 5 PCs of 35 
SNPs was marginally significantly associated (p=0.0194) with change in A1c (Table 
5.3). The next most significant (p=0.0614) gene was SLC29A4, the gene coding for 
plasma membrane monoamine transporter (PMAT). The Locus Zoom plots (Figure 5.2) 
identified some linkage disequilibrium for 4 SNPS in PRKAB2 but were far from the 
most significant SNP (rs7541245,p=0.0019), the SNP of interest, based on the 1000 
Genomes European reference population from March 2012 release. Blocks of linkage 
disequilibrium (Figure 5.3) were designated within the PRKAB2 and SLC29A4 genes. 
Gene-level analysis does not give a direction of the associations; SNPs within a gene can 
have both negative and positive associations with the outcome. An alternative SNP-level 
analysis was performed to gain insight in to the directionality of these associations.  
Figure 5.2: Locus Zoom plots for select candidate genes. 
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Figure 5.3: Linkage Disequilibrium (LD) blocks. The LD values as measured using r2 are 
given by numbers and the LD values as measured by D’ are shown by color intensity (red squares 
indicate strong LD, pink squares indicate intermediate LD, and white squares indicate low LD, 
with evidence for ancestral recombination; blue indicates limited data). 
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SLC29A4 
 
3.2.  SNP-Level Results of Two Most Significant Candidate Genes 
 48 SNPs in 2 significant or marginally significant candidate genes were evaluated 
for directionality. 5 SNPs (rs6665580, rs6659191, rs6678588, rs7541245, rs10494243) in 
high LD within PRKAB2, a PD determinant, were found to be significantly associated 
with a decrease in glycemic response after metformin exposure. 1 SNP (rs10234709) in 
SLC29A4, a PK determinant, was found to be significantly associated with a decrease in 
glycemic response after metformin exposure. Detailed SNP-level associations can be 
found in Table 5.4. 
3.3.  SNP-Level Results of Remaining Candidate Genes 
 Adjusted SNP-level analysis (Table 5.5) of non-significant candidate genes found 
variation in SNPs (n=425) for the genes PRKAA1 (1), PRKAG2 (3), SLC22A3 (2), 
SLC47A1 (4), SLC47A2 (2), and STK11 (1) to be significantly associated with change in 
glycemic response after metformin exposure. However, gene-level analysis did not 
identify significant variation within these genes and after applying Bonferroni correction 
for multiple testing no SNPs could be considered significant with the lowered 
significance threshold (p<1.1765E-4). 
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Table 5.5: SNP-level Analysis of Non-significant Candidate Genes 
SNP MA BETA P-value Gene Name 
rs4725434 T 0.2211 0.0136 PRKAG2 
rs3127602 T 0.2307 0.0147 SLC22A3 
rs3123629 A 0.2266 0.0168 SLC22A3 
rs12539356 T 0.2312 0.0211 PRKAG2 
rs2120274 A 0.1938 0.031 SLC47A1 
rs1534665 C -0.1942 0.0318 PRKAG2 
rs2301759 C 0.2203 0.0345 STK11 
rs2453586 A 0.1849 0.0385 SLC47A1 
rs4621031 C -0.1908 0.041 SLC47A2 
rs962801 T -0.1909 0.0414 SLC47A2 
rs11749180 A -0.208 0.0464 PRKAA1 
rs2245639 C 0.1755 0.0493 SLC47A1 
rs2165895 A 0.1755 0.0493 SLC47A1 
MA = Minor Allele 
 
SNP Minor Allele
Major 
Allele MAF BETA 95% CIs P-value SNP
Minor 
Allele
Major 
Allele MAF BETA 95% CIs P-value
rs7541245 A C 0.0311 -0.7885 (-1.28;-0.297) 0.0019 rs2354432 C T 0.1376 -0.0685 (-0.317;0.180) 0.5894
rs6678588 C A 0.0330 -0.6809 (-1.163;-0.199) 0.0060 rs12401360 G A 0.2287 0.0485 (-0.149;0.246) 0.6310
rs6659191 C T 0.0330 -0.6809 (-1.163;-0.199) 0.0060 rs894467 C T 0.0310 0.1036 (-0.368;0.575) 0.6667
rs6665580 G A 0.0330 -0.6809 (-1.163;-0.199) 0.0060 rs894470 A G 0.0310 0.1036 (-0.368;0.575) 0.6667
rs10494243 T C 0.0330 -0.6809 (-1.163;-0.199) 0.0060 rs7546434 A G 0.0310 0.1036 (-0.368;0.575) 0.6667
rs718369 C T 0.2810 -0.1834 (-0.374;0.007) 0.0607 rs4534444 T C 0.0310 0.1036 (-0.368;0.575) 0.6667
rs2077749 A G 0.3159 -0.1631 (-0.34;0.014) 0.0719 rs2354434 A G 0.0310 0.1036 (-0.368;0.575) 0.6667
rs6937 C T 0.1376 0.2096 (-0.032;0.451) 0.0897 rs10900321 T C 0.3895 0.0245 (-0.151;0.2) 0.7849
rs2304893 C T 0.0659 0.2813 (-0.062;0.624) 0.1093 rs1036851 C T 0.3895 0.0245 (-0.151;0.2) 0.7849
rs2297753 A G 0.0659 0.2813 (-0.062;0.624) 0.1093
rs4950385 A G 0.0640 -0.2787 (-0.619;0.062) 0.1101
rs6703847 G A 0.0640 -0.2787 (-0.619;0.062)
rs894469 C T 0.0640 -0.2787 (-0.619;0.062) 0.1101 rs10234709 A C 0.3852 -0.1987 (-0.379;-0.018) 0.0318
rs7523812 G A 0.0640 -0.2787 (-0.619;0.062) 0.1101 rs10279978 A G 0.2965 0.1878 (-0.013;0.388) 0.0678
rs894471 G A 0.0640 -0.2787 (-0.619;0.062) 0.1101 rs13238999 A C 0.3839 -0.1473 (-0.317;0.023) 0.0911
rs17159924 G A 0.2461 -0.1234 (-0.321;0.074) 0.1101 rs10951853 T C 0.4593 -0.1406 (-0.304;0.022) 0.0923
rs1932977 C T 0.2539 -0.1064 (-0.298;0.085) 0.2222 rs6943227 G T 0.2829 0.1341 (-0.055;0.324) 0.1668
rs4950386 A G 0.0252 0.2541 (-0.257;0.765) 0.2781 rs7904 T C 0.3547 -0.1124 (-0.292;0.067) 0.2207
rs1822311 T C 0.0252 0.2541 (-0.257;0.765) 0.3305 rs6463343 A G 0.4360 -0.0896 (-0.268;0.088) 0.3249
rs6593746 G A 0.0252 0.2541 (-0.257;0.765) 0.3305 rs6958502 A G 0.2074 -0.0888 (-0.302;0.124) 0.4143
rs894473 A G 0.0261 0.2553 (-0.262;0.772) 0.3305 rs10278799 T C 0.0717 0.1049 (-0.229;0.438) 0.5383
rs11811023 C T 0.2713 -0.0843 (-0.277;0.108) 0.3339 rs4577873 A G 0.4554 0.0507 (-0.116;0.217) 0.5508
rs1348316 G A 0.4225 -0.0602 (-0.231;0.111) 0.3912 rs3889348 A G 0.3643 0.0271 (-0.151;0.205) 0.7656
rs750467 T C 0.1686 0.0709 (-0.148;0.29) 0.4913 rs10226233 T C 0.3488 -0.0109 (-0.181;0.159) 0.9003
rs3766521 C A 0.0039 0.4161 (-0.960;1.792) 0.5270 rs11971512 G A 0.4147 0.0103 (-0.159;0.180) 0.9052
rs6690158 T C 0.0039 0.4143 (-0.96;1.788) 0.5550
P-value
MAF = minor allele frequency
Table 4: SNP-level Analysis of Significant or Marginally Significant Candidate Genes
PRKAB2 PRKAB2 (cont.)
SLC29A4
SNP
Minor 
Allele
Major 
Allele MAF BETA 95% CIs
Table 5.4: 
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4.  Discussion 
 The primary purpose of this study was to add clarity to metformin 
pharmacogenomics by understanding the impact of common variants in metformin 
candidate genes (n=17) on altered glycemic response in a clinical population derived 
from an EHR-linked biorepository. All candidate genes were selected due to a suspected 
role in metformin PK/PD. Gene-level and SNP-level variants were found to be associated 
with decreased glycemic response to metformin.  
4.1.  Interpretation of associations  
 Gene-level analysis found variation in the PD candidate PRKAB2 gene to be 
significantly associated with change in glycemic response after exposure to metformin. 
SLC29A4 was found marginally significant (P-value=0.0614) in gene-level analysis. 
SNP-level analysis confirmed variations in both PRKAB2 and SLC29A4 genes to be 
associated with decreased glycemic response. While the additional SNP-level analysis for 
non-significant gene-level associations identified significant SNPs within the PRKAA1, 
PRKAG2, SLC22A3, SLC47A1, SLC47A2, and STK11, these SNPs are no longer 
significant after adjusting for multiple testing and cannot be meaningfully interpreted.  
4.2.  Molecular significance of associations 
 AMPK is a heterotrimeric enzyme composed of alpha, beta, and gamma subunits, 
encoded by 5 genes, each of which uniquely determines protein stability and activity. 
AMPK acts as a metabolic master switch regulating several intracellular systems and 
plays an important role in cellular energy homeostasis, the maintenance of cellular ATP 
levels[19]. Metformin is a known AMPK activator, with genetic variations in AMPK 
suspected to impact the response to metformin[11]. In this study we found variations in 
PRKAB2 (AMPK-B2), a PD determinant, to be associated with decreased change in 
glycemic response to metformin. While some SNPs in PRKAA1 and PRKAG2 subunit 
coding genes were potentially implicated in impacting change in glycemic response, an 
association was not identified in the gene-level analysis. Despite suspected AMPK 
involvement in response to metformin, the specific targets of metformin are not clearly 
understood. In this study we identified 3 LD blocks within the PRKAB2 gene that 
62 
deserve further investigation for developing personalized metformin therapy 
considerations. 
 The SLC29A4 gene, encoding for the PK determinant PMAT, is the primary source 
of metformin absorption in the intestine[2], having systemic implications for metformin 
availability via the bloodstream. While gene-level analysis identified a marginally 
significant association, the locus zoom (Figure 5.2) and LD plots (Figure 5.3) identified 
low linkage disequilibrium across the gene. SNP-level analysis points to the identified 
variant (rs10234709) as being associated with decreased glycemic response to metformin. 
Of note is the exploratory SNP-level analysis that identified covariate adjusted significant 
associations for SNP variants (rs3127602 and rs3123629) in the SLC22A3 gene with 
increases in glycemic response to metformin. SLC22A3 is the gene that encodes for 
OCT3, which is also known to be responsible for intestinal absorption of metformin and 
is also implicated in metformin uptake in the liver from the blood. Finally OCT1, 
encoded by SLC22A1, is responsible for uptake of metformin into the blood from the 
intestine and has been previously found to be associated with glycemic response[20]; our 
study found no such association. While we find some evidence pointing towards the 
importance of intestinal absorption of metformin in modifying glycemic response, the 
evidence is not clear.  
 In addition to the filtered gene-level analysis, our exploratory SNP-level analysis of 
non-significant candidate genes identified some findings of note. SNP-level variation in 
SLC47A1, a gene that encodes for MATE1, a PK determinant that is expressed in the 
liver, appears to be associated with increased glycemic response to metformin. While this 
evidence only hints at a potential association, variation in this transporter is clinically 
relevant due to potential drug-drug interactions that can occur in liver with transporter 
variation[7], further study is needed. Regarding PD determinants, kinases such as 
ATM[21] or STK11[22] are thought modulate AMPK activity by metformin[23]. While 
we able to identify rs2301759 as a significant (beta=0.2203,p=0.0345) covariate  adjusted 
SNP within the STK11 gene, it is important to note that Bonferroni correction negates 
significance of this association. We were unable to identify a significant association 
between ATM variation and glycemic response to metformin with the lowest covariate 
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adjusted SNP (rs1800058) having a p-value of 0.1546. 
4.3.  Strengths and Limitations 
 In this study, we leverage EHR-linked biorepository data and EHR-based 
phenotyping methods to study variants associated with Metformin PD and PK. While our 
cohort is modestly powered (N=258), we posit that utilizing a clinical endpoint that is 
sensitive to PD and potentially PK determinants strengthens our study. However, relying 
solely on the endpoint of glycemic response has potential to bias PK associations towards 
the null as PK alterations might only indirectly impact glycemic response. In particular, 
due to the wide distribution and systemic impact of metformin the distinction between 
PK and PD determinants may not necessarily be distinct at the clinical level. Further, 
while the genetic contribution to variation in metformin renal clearance in the kidneys is 
estimated to be approximately 90%[24], bioavailability and concentration of metformin 
likely will very widely based on renal function, topics that will be addressed in our future 
work.  
 Like most existing pharmacogenomic studies of metformin we have utilized a 
candidate gene approach that focuses PK implications on transporters[2]. However, our 
study includes PD determinants, which are not as thoroughly understood, to increase our 
understanding of metformin pharmacogenomics. Further, not all SNPs within candidate 
genes were available for analysis due to GWAS sequencing being originally performed 
for other studies. The secondary nature of the GWAS data has potential to bias findings 
either due to original patient selection criteria or sequencing criteria. Finally, while an 
agnostic training step was not utilized to identify candidate genes, our selection of 
candidate genes draws strength from the large body of literature on which it is based. Our 
work seeks to clarify the associations and importance of genes speculated in the literature 
as being PK or PD determinants of metformin. 
4.4.  Implications and prospects for personalized medicine  
 Advances in pharmacogenomics are needed to understand the relationship between 
genetic variation in key proteins, like those included in this study, and PD 
implications[11]. Further, with the potential repurposing of metformin in cancer 
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prevention and treatment it is important to understand the pharmacogenomics of 
metformin in both T2DM and cancer. While the development of personalized metformin 
therapy benefits from understanding pharmacogenomic associations such as these, further 
insight into the mechanism of metformin action is needed. Further, the utilization of 
multi-omics approaches might be considered to identify additional metformin targets 
[4,23]. Additional information clarifying further metformin pharmacogenomics will make 
it possible to develop personalized metformin therapies. In this study we identified 
potential biomarkers that alter the clinically relevant outcome of glycemic response to 
metformin. 
5.  Conclusion 
 PRKAB2, the gene encoding the beta subunit 2 of adenosine monophosphate-
activated protein kinase complex, appears to be associated with decreases in glycemic 
response after exposure to metformin, with rs7541245 having the strongest SNP 
association. SLC29A4, the next most significant gene, with rs10234709 having the 
strongest SNP association, has potential to also be associated with decreases in glycemic 
response after exposure to metformin. In this study we were able to replicate a metformin 
PD determinant and potentially a metformin PK determinant using an intermediary 
phenotype powered by EHR-linked biorepository data.  
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Chapter 6: Leveraging an Electronic Health Record-Linked Biorepository to 
Generate a Metformin Pharmacogenomics Hypothesis 
Abstract  
 Metformin is a first-line antihyperglycemic agent commonly prescribed in type 2 
diabetes mellitus (T2DM), but whose pharmacogenomics are not clearly understood. 
Further, due to accumulating evidence highlighting the potential for metformin in cancer 
prevention and treatment efforts it is imperative to understand molecular mechanisms of 
metformin. In this electronic health record(EHR)-based study we explore the potential 
association of the flavin-containing monooxygenase(FMO)-5 gene, a biologically 
plausible biotransformer of metformin, and modifying glycemic response to metformin 
treatment. Using a cohort of 258 T2DM patients who had new metformin exposure, 
existing genetic data, and longitudinal electronic health records, we compared genetic 
variation within FMO5 to change in glycemic response. Gene-level and SNP-level 
analysis identified marginally significant associations for FMO5 variation, representing 
an EHR-driven pharmacogenetics hypothesis for a potential novel mechanism for 
metformin biotransformation. However, functional validation of this EHR-based 
hypothesis is necessary to ascertain its clinical and biological significance.  
Introduction 
 Metformin is a first-line antihyperglycemic agent commonly prescribed for type 2 
diabetes mellitus (T2DM) patients1, whose pharmacogenomics are not clearly 
understood2, but are thought to be absent of biotransformation3. Further, glycemic 
response to metformin is variable3 and serious adverse reactions to metformin have been 
known to occur4. Due to increasing evidence highlighting the potential for metformin in 
cancer prevention and treatment, it is imperative to understand molecular mechanisms of 
metformin further. 
Background 
 Metformin is primarily utilized to regain glycemic control in diabetic or pre-
diabetic patients. Metformin is a relatively safe antidiabetic therapy5. However, serious 
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adverse reactions can occur4 and there is considerable variation in glycemic response to 
metformin, with ~30% of patients unable to achieve glycemic control with metformin3. 
While genetic factors may partially explain clinical glycemic response to metformin due 
to pharmacokinetic(PK) determinants3, the transportation throughout the body variation, 
the identification and impact of metformin pharmacodynamic(PD) determinants, the 
physiological and biochemical impact of metformin in the body, remains uncertain2. 
Regarding PKs, Metformin is thought to not be metabolized3, with absorption of 
metformin known to occur in the small and large intestines5. Uptake of metformin from 
the blood is known to occur in the kidneys and liver2, but can be reasonably assumed to 
occur in any tissue with abundance of organic cation transporters (OCT). Eventually 
metformin is excreted unchanged in the urine5. Regarding PDs, metformin works 
primarily by inhibiting hepatic glucose production by reducing gluconeogenesis in the 
liver6 and is also known to reduce intestinal glucose absorption7. Further, metformin 
appears to improve glucose uptake and utilization systemically3.  
 Metformin is a nitrogen-rich biguanide. Flavin-containing monooxygenases(FMO)-
5 has demonstrated narrow substrate specificity, but has been known to catalyze 
oxygenation of nitrogen-containing drugs8. FMO5 is expressed in the kidneys and liver8. 
The FMO5 gene exists near PRKAB2, a known PD regulator of metformin response, 
away from the single gene cluster for the remaining FMOs in chromosome 1q23-q25 
region. Metformin is excreted unchanged in the urine5, hinting that metformin does not 
undergo biotransformation. However, studies such as these do not produce 100% yield, 
hinting at room for deviation from this paradigm. While metformin is thought to be 
absent of biotransformation3, it is biologically plausible that FMO5 might carry out N-
oxygenation of metformin. 
 FMOs show overlapping substrate specificity among family members8; a signal 
corresponding to FMO5 might also correspond to an additional FMO gene. All FMOs 
contain eight coding exons that share 50 to 80% sequence identity, with mutant FMOs 
are known to react to alternative chemical sites9. FMOs are localized in the endoplasmic 
reticulum of the cell whose expression is tissue-specific8. The extent of which reactions 
are catalyzed by FMOs in vivo cannot be determined by measuring end products excreted 
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in bile or urine10.  
 The primary purpose of this study was to add clarity to metformin 
pharmacogenomics by understanding the impact of common variants in the FMO5 gene 
on altered glycemic response in a clinical population derived from an EHR-linked 
biorepository. Due to some shared functional similarity among genes in the FMO gene 
family, we selected the remaining FMO genes (FMO1 – FMO4) as exploratory gene 
candidates as our secondary hypothesis. 
Methods 
 In this EHR-linked genetic study, both the approaches for obtaining clinical 
phenotypes and genotypes had important considerations for both study design and study 
interpretation. Our primary hypothesis of interest holds that genetic variation within 
FMO5 has potential to modify glycemic response to metformin monotherapy. Secondary 
to the primary hypothesis is an exploratory hypothesis that posits similar potential 
associations for FMO1 – FMO4 due to functional similarity8. However, their function is 
not identical.  Further, due to the close proximity of the FMO1 – FMO4 to each other and 
their relative distance from FMO5 on chromosome 1q21 our secondary hypothesis is 
considerably weaker than our primary hypothesis for FMO5.  In this study, we utilized 
the longitudinal EHR at Mayo Clinic and genome-wide association study (GWAS) data 
from the subjects enrolled in the Mayo Genome Consortia (Mayo GC)11.    
Clinical Phenotypes 
 The application of EHR-based phenotypes dramatically impacts study design and 
interpretability of findings. In this study we had 4 key phenotype aspects to consider: 1) 
T2DM phenotype, 2) metformin exposure phenotype, and 3) change in A1c. First, 
attribution of a T2DM phenotype was performed using a modified methodology 
developed by eMERGE12. A key point of differentiation is that our T2DM phenotype 
relied on diagnosis codes and did not initially consider laboratory values or medication. 
However, our second and third considerations relied on lab values and medication 
exposure events that were more specific than the criteria for the eMERGE T2DM 
phenotype algorithm. Second, our metformin exposure period was designated as a new 
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prescription of metformin that extended ≥6 months to ensure adequate primary care 
visits, multiple A1c measures, and maintenance dose achievement. Since our study aimed 
to understand genomic variation in relation to patients who respond or do not respond to 
metformin, maintenance dose was not a consideration. To accurately populate this 
metformin exposure phenotype our study design required longitudinal data access from 
primary care patients. Specifically, study inclusion criteria required ≥1 year of patient 
history and ≥2 primary care visits to ensure accurate capture of the first date of 
metformin exposure, which aimed to exclude patients that were false positives for a new 
recorded exposure to metformin due to medication reconciliation that occurred at transfer 
of primary care. Metformin exposure events were ascertained using a combination of 
validated structured and semi-structured EHR data collection methodologies that 
leveraged our prior work13,14 where a total of 1 generic name (metformin) and 4 brand 
name medications (Fortamet®, Glucophage®, Glumetza®, and Riomet®) were queried. 
Patients with <6 months of metformin exposure or on combination drugs that included 
metformin or other prescribed antidiabetic drugs during the ≥6 month exposure period 
were excluded from the study. Third, to compare the association of genetic modification 
to glycemic response to metformin, measures of A1c were compared prior to metformin 
exposure and during the period of metformin exposure following a 6-month period of 
delay to allow for the achievement of maintenance dosage. A1c measures were required 
≤6 months prior to metformin exposure and ≥6 months after metformin exposure. A1c 
measures were averaged across sections that occurred before and up to the date of 
metformin exposure. A1c measures were averaged across the period occurring ≥6 months 
after initial metformin exposure and until either metformin exposure ceased or anti-
diabetic combination therapy was initiated. This approach minimizes the impact of any 
one A1c measure and biases change in A1c measures towards the null.   
Genotyping and Quality Control  
  The Mayo GC stores existing GWAS data generated from multiple studies. These 
data were harmonized to the forward strand mapped to become on the same strand as the 
1000 genome cosmopolitan reference population. Genotypes for unmappable or 
ambiguous SNPs were excluded.  We selected SNPs 20 kb upstream and downstream of 
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each gene using 1000 genomes project variants and NCBI build 37 as the reference 
genome. By this mapping rule, a total of 1,381 SNPs were mapped to the 5 genes, but 
only 205 SNPs were available in the genotype data. Further, due to their proximity the 
FMO1, FMO2, FMO3, and FMO4 genes some SNPs belong to multiple genes. For the 
remaining SNPs, two main quality control filters were applied:(i) SNPs with 
unacceptable high rates of missing genotype calls (>10%); and (ii) monomorphic SNPs 
were excluded. The quality control of the genotype data was performed by PLINK 
v1.0715. A detailed diagram of cohort development is found in Figure 6.1. 
Figure 6.1: Study Cohort Development Process 
 
Analysis  
 The SNP-level and gene-level analyses were performed on the final analysis cohort 
where 258 Caucasian subjects had metformin exposure, complete EHR data, and 90 
SNPs after quality control. In the analysis, we adjusted for age, gender, and morbid 
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obesity (BMI ≥35), a known modifier of T2DM state1 as fixed covariates in our model. 
Age and BMI measures were calculated at first recorded exposure to metformin. The 
endpoint of change in A1c was transformed using Van der Waerden rank, otherwise 
known as rank based inverse Gaussian, to normalize and accommodate linear regression 
modeling.  Batch adjustment did not change the results of GWAS data (data not shown) 
and was not adjusted in the displayed results. SNP-level and gene-level results were 
described, but not displayed, after application of Bonferroni correction.    
SNP-Level Analysis  
 SNP-level analyses were performed on each SNP in FMO genes pertaining to both 
our primary and secondary hypothesis to identify top SNPs and determine directionality 
of their associations.  Using Van der Waerden rank transformation on change in A1c, 
linear regression models were applied adjusting for age, gender and morbid obesity. 
Coefficient estimates were calculated per minor allele, that is, with each minor allele, the 
A1c level changes by ‘beta’. SNP-level results are displayed as unadjusted for multiple 
testing. Finally, similar analysis adjusting for the top SNP was performed to identify 
potentially independent SNPs in each gene.  Locus Zoom plots were also created for 
better visualization using the LD in the 1000 Genomes European reference population 
from March 2012 release.  
Gene-Level Analysis  
 Gene-level tests were performed using principal component analysis (PCA)16. For 
each gene, principal components (PC) were created using linear combinations of 
ordinally scaled SNPs (i.e., 0, 1, 2 copies of minor allele) and the smallest set of resulting 
principal components that explained at least 90% of the SNP variance within the gene 
was included in linear regression models. Instead of including the entire set of SNPs for 
each gene, the PC approach reduces the degrees of freedom, avoids model fitting issues 
due to multi-collinearity of the SNPs from linkage disequilibrium (LD) and potentially 
improves the statistical power. Finally, we computed the likelihood ratio test (LRT) to 
assess overall significance of a gene by comparing the null model containing only the 
covariates with the full model containing covariates and the set of resulting principal 
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components. The statistical package R 2.15.0 was utilized for the gene-level analysis. 
Plots of LD displaying r2 for FMO5 gene was created using Haploview v 4.2.  
Results 
 Our EHR-based phenotyping algorithm identified 1,793 T2DM subjects (Figure 
6.1). Among those, 258 subjects had 90 SNP data that passed quality control criteria. 
Cohort demographics can be found in Table 6.1. The estimates for male 
(Coefficient=0.0435, P-value=0.737), age (Coefficient=-0.0009, P-value=0.881), morbid 
obesity (Coefficient=0.2214, P-value=0.083) were not significantly associated with 
change in A1c at alpha=0.05 significance level in the univariate analysis. Further, none of 
the covariates were associated with change in A1c at alpha=0.05 significance level in a 
multivariate model. 
Table 6.1: Demographics (n=258) 
Variable n   (%) 
Female, N(%) 89    (34.5)	  
Male, N (%) 169  (64.5)	  
BMI <30, N (%) 64    (24.8)	  
BMI(≥30 to <35 kg/m2) 100  (38.8) 
BMI ≥35 (kg/m2) 93    (36.1)	  
Median A1c >7.0 
(DCCT %), N (%) 101  (39.1)	  
Change in A1c (DCCT %), 
median (range) 
0.07	  
(-6.45, 3.51)	  
Age (years),  
median (range) 
64	  
(30, 84) 
SNP-Level Results 
 Among 31 genotyped SNPs within FMO5 gene, 4 SNPs had p-values less than 0.05 
for the association with a decrease in glycemic response during metformin exposure, with 
rs7541245 having the most significant signal. While after adjusting for multiple testing 
rs7541245 was marginally significant, this signal is vey close to passing correction 
(0.00188-observed vs. 0.00161-Bonferonni threshold), and was still appropriate for 
consideration.  None of the SNPs in FMO1-FMO4 gene cluster were found to be 
significant. The FMO5 linkage disequilibrium (LD) plot (Figure 6.2) contained 4 LD 
blocks and appeared to show 9 independent SNPs. The conditional analysis that adjusted 
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Figure 6.2: FMO5 Linkage Disequilibrium Blocks 
 
Figure 6.3: FMO5 Locus Zoom Plot 
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for the top most significant SNP in each gene and clinical covariates was performed. 
FMO5 rs7541245 was the main signal on FMO5 gene as no SNPs reached p-values less 
than 0.05 which pointed to the remaining SNPs within FMO5 being in high LD with 
rs7541245 and hence, not independent. The Locus Zoom plot for FMO5 can be found in 
Figure 6.3. For reference purposes only, a Locus Zoom plot containing FMO1 – FMO4 
can be found in Figure 6.4. 
Figure 6.4: Locus Zoom plot for FMO1 – FMO4 
 
Gene-Level Results 
 Our primary hypothesis for the FMO5 gene, 
represented by 5 PCs and 31 genotyped SNPs, was 
marginally significantly associated (p=0.0185) with 
glycemic response (Table 6.2) after controlling for 
age, gender and morbid obesity. No significant associations were identified for our 
secondary hypothesis tests of the remaining FMO genes. 
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Table 6.2: Principal Component 
Analysis 
Gene  Genotyped SNPs (n) nPCs P-value 
FMO5 31 5 0.0185 
FMO4 12 4 0.5623 
FMO3 14 5 0.5464 
FMO2 19 4 0.3581 
FMO1 15 6 0.5479 
76 
 Discussion 
 In this study, we leverage EHR-linked biorepository data and EHR-based 
phenotyping methods to study common variants within FMO5, our gene of primary 
interest. While the FMO5 gene appeared to be of marginal significance in relation to 
glycemic response to metformin, our secondary hypothesis for the remaining FMO genes 
demonstrated no significance. Given the study design and execution of phenotypes, 
results of this study can be interpreted most accurately as pharmacogenetics hypothesis 
generating. However, this hypothesis could represent a novel mechanism for the 
biotransformation of metformin and mechanism of metformin action that has been 
previously unidentified. Functional studies are indeed warranted. 
 In our study not all SNPs within candidate genes were available for analysis due to 
GWAS sequencing being originally performed for other studies. No effect difference was 
observed between cohort batches which indicated that our findings were not biased due to 
original patient selection criteria or sequencing criteria. Having all patients with T2DM 
and metformin allowed for us to identify genetic variation as the consideration of interest. 
However, the limited sample size paired with a relatively weak clinical outcome had 
potential to bias associations towards the null. While utilizing a clinical endpoint enabled 
us to engage in exploratory research, our signal strength was limited by modest cohort 
size (n=258) and the study criteria design. Specifically, by removing patients with <6 
months of metformin exposure during metformin exposure we potentially removed 
patients who were complete non-responders to metformin or who experienced an adverse 
reactions to metformin. By study design these would not have been able to attain 
glycemic control with metformin, biasing our outcome phenotype towards positive 
glycemic response (i.e. decreased A1c) to metformin. 
 Alterations in FMO genes are known to induce differential biotransformation of 
nitrogen-rich compounds, such as metformin10. In this study, it appeared that the utility of 
metformin (i.e. glycemic response) is impaired by alterations in the FMO5 gene, hinting 
that potential biotransformation of metformin might be occurring in the normal FMO5 
gene product. Our finding hints that metformin conjugates resulting from metformin 
biotransformation via FMO5 might be responsible for the anti-diabetic effects of 
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metformin. Should these findings be confirmed by functional studies, this hypothesis 
could represent a novel mechanism for the biotransformation of metformin and 
mechanism of metformin action that has been previously unidentified.  
Conclusion 
 FMO5 appears to be marginally significantly associated with decreases in glycemic 
response after exposure to metformin, representing an EHR-driven pharmacogenetics 
hypothesis that could represent a novel mechanism for the biotransformation of 
metformin that has been previously unidentified. Functional validation of this hypothesis 
is warranted to ascertain its clinical and biological significance.  
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V. Conclusion 
Chapter 7: Conclusion for the Framework on Translational Informatics 
 In this dissertation I utilized informatics-driven data acquisition to answer a line of 
scientific inquiry regarding the pharmacogenomics and pharmacoepidemiology of 
metformin in breast cancer and T2DM that was centered on the Multilevel Framework 
for Translational Informatics (Figure 1.1). In this work I addressed three topics of 
relevance: 1) pharmacoepidemiological modeling using EHR-data, 2) incorporating 
population-level socioecological context into clinical research, and 3) leveraging an 
EHR-linked biorepository to test and develop pharmacogenetic hypotheses. Together, 
these parts highlighted some of the nuances in utilizing data from different levels to 
elucidate clinical questions. Individually, I was able to 1) demonstrate that metformin has 
a protective effect and insulin a detrimental effect on breast cancer treatment outcomes 
that is beyond their implication for T2DM severity, 2) develop an Socioecological 
Conditions (SEC) Index that was significant and improved model performance for 
predicting breast cancer performance, and 3) develop an EHR-driven molecular 
hypothesis for the potential biotransformation of metformin via FMO5, a novel 
mechanism. While this work elucidated aspects of breast cancer pharmacogenomics, it 
primarily aimed to demonstrate this framework for utilizing informatics approaches to 
drive metformin pharmacoepidemiology and translational pharmacogenomics for 
potential metformin repurposing in breast cancer treatment and similar research in the 
future. 
From an informatics perspective the contributions of this dissertation include: (i) 
multilevel integration of data from a molecular level to socio-ecological level and (ii) 
capturing exposure phenomena from large-scale (EHR-scale) data through the SEC 
Index, which is an enabling technology for integrating SECs with clinical data. These 
contributions are very well aligned with the NCI’s strategic goals for biomedical 
informatics that I briefly described in the Prelude. As the field of biomedical informatics 
proceeds forward towards data science, relying on reference points that appropriately 
frame the starting points or boundaries (i.e. premises) become increasingly important. 
Specifically, since biomedical scientists do not have the luxury to gain knowledge from 
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near-unlimited data access for algorithm training that is available on internet, robust 
premises become a critical tool to focusing data power to analysis-specific 
computationally and scientifically relevant calculations. Further, as we think about the 
needs of cancer epidemiology the more we see the need for multilevel modeling powered 
by scalable and portable informatics-driven approaches.   
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